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Chapter 1. 
Introduction 
Stress ulcers (SU) are acute ulcers which develop in the stomachs 
of severely ill patients. Erosions and acute hemorrhagic gastritis are 
included in the term stress ulcers. Bleeding from such a lesion is 
called a stress bleed (SB). The oldest description of SU is probably 
that of Aulus Cornelius Celsus (1) who described its development in 
Roman soldiers wounded in battle. In 1772 John Hunter (1) reported 
"malacia of the stomach" at autopsy examinations, and he considered 
this to be a lesion which developed before death as a result of a 
serious illnes. Curling described in 1842 the acute duodenal ulcers in 
patients with severe burns (2). Gastric ulcers occurring in burned 
patients were later also included in the definition of Curling's 
ulcers. Rokitansky described "decubity of the gastric mucosa" in the 
proximal portion of the stomach in 1846 (3). His description was based 
on post mortem examinations of patients who had died after severe 
illness. With better medical care and improving prognosis of 
previously lethal diseases. the realization grew that this type of 
gastric damage caused clinical problems in the form of hemorrhage. In 
1932 Cushing published the association between ulcers in the upper 
gastrointestinal tract and brain disease (4). 
In the second world war a number of patients were reported with 
burns who survived the initial fase due to administration of plasma 
and other solutions, but who subsequently developed sepsis complicated 
by stress bleeds. 
During the past 20 years the association between major trauma and 
hypovolemic shock and SB has become clearer. Stress bleeds often 
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develop after a number oi days in these patients, especially when 
major trauma is complicated by a shock lung, renal insufficiency or 
sepsis. These problems were described extensively in casualties in the 
Vietnam war and following traffic accidents. Major operations 
performed in older or previously severely ill patients form another 
group in whom SB is seen. 
The problem of SB is a problem of the intensive care department. 
The following conditions have been reported to predispose to SU or SB: 
respiratory insufficiency, hypotension, sepsis, peritonitis, renal 
insufficiency, major operations, major trauma and jaundice (1,5,6,7). 
These clinical conditions can be called risk factors. Although 
extensive burns and brain disease can also lead to ulceration in the 
stomach, they are often associated with duodenal and/or esophageal 
lesions. The gastrointestinal lesions associated with burns and brain 
disease are complicated not only by bleeding but also by perforation. 
For these and other reasons, described in chapter 2 and 3, they differ 
morphologically and pathophysiologically from the stress ulceration. 
The gastric ulceration or erosive gastritis associated with the risk 
factors is practically never associated with perforation but is 
clinically of importance because it often results in gastrointestinal 
hemorrhage. The incidence of SU reported in the literature varies. In 
one group of trauma patients, stress lesions were fou..TJ.d in all 
patients on endoscopy (6). Stress bleeding occurs in 5-20% of patients 
in an intensive care unit (5,8,9). Clinically manifest bleeding from a 
SU has a mortality of more than 30% (10). 
Optimal medical care is the basis of the prophylaxis of SB. A 
prompt treatment of complications or risk factors (e. g. sepsis) is 
essential. The chance of developing SB is related to the number of 
risk factors (1,5,6). As not all risk factors can be rapidly reversed, 
specific prophylaxis of SB is desirable. 
Hastings et al (7), using guaiac tests for determination of blood 
loss, showed that the incidence of SB could be reduced from 25% to 6% 
by titration of gastric contents with antacids to a predetermined pH. 
Priebe et al (11) compaired antacids with the histamine-2-antagonist 
cimetidine in stress bleeding prophylaxis. They found that cimetidine 
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failed to protect against stress bleeding. These findings were 
confirmed by Zinner et al (9) and Van den Berget al (12). The role of 
gastric acids in the development of SU is not clear. The primary 
damage associated with the above mentioned risk factors is ~pparently 
to the gastric mucosa and diminished perfusion of the gastric mucosa 
seems to play a major role. Prostaglandins have been shown to be of 
great importance in the maintenance of the integrity oi the gastric 
mucosal barrier. They have been demonstrated to protect the gastric 
mucosa against damage by acetylsalicylic acid (13) and absolute 
alcohol (14). This effect of prostaglandins ha::;; been called 
cytoprotection (14,15,16). Although some prostaglandins (PGE1 , PGE2 , 
PGA1) can reduce gastric acid production when given in large doses, 
the cytoprotective effects on the gastric mucosa are not dependent on 
a reduction of gastric acidity (17). 
To determine the possible clinical applications of the 
cytoprotective effects of prostaglandins in the prophylaxis of SU and 
SB we performed a clinical study in intensive care patients. In this 
study we used prostaglandin E2 , the prostaglandin that is normally 
present in gastric mucosa (18). The results of this study are 
.described in chapter 5. In chapter 2 stress ulcers are discussed 
further with regard to the localization and the histology. In chapter 
3 the pathophysiology of stress ulcers is described in detail, and the 
evidence for cytoprotection by prostaglandins in chapter 4. The 
patients, methods and results of the clinical study are reported in 
chapter 5. In chapter 6 problems associated with the measurement of 
blood loss in gastric juice are described. In chapter 7 a new method 
we developed to measure gastrointestinal blood loss quantitatively is 
reported. Chapter 8 describes DNA measurements in gastric juice. 
Chapter 9 contains a general discussion on the treatment and 
prevention of stress ulcers and stress bleeds. Finally, a discussion 
and summary is given in chapter 10. 
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Chapter 2. 
Pathology of stre:;s ulcers 
2.1 LOCALIZATION AND MACROSCOPY 
Stress ulcers are usually multiple and occur mainly in the proximal 
part of the stomach. Skillman et al (1) found multiple superficial 
ulcers in the fundus of the stomach in six patients with respiratory 
insufficiency, hypotension, sepsis and jaundice who had had massive 
gastrointestinal hemorrhage. The antrum was involved in only one 
patient, in addition to the lesions in the fundus. The lesions varied 
in size from 0.2 em. to 4.0 em. in diameter. Erosions are almost 
always present at the same time as ulcers (2,3). Ulcers develope from 
erosions, as has been shown by the studies of Lucas et al (4) who 
performed serial gastrophotography studies in 42 seriously ill 
patients with sepsis and/or trauma. Within the first 24 hours pale 
areas were seen in the proximal portion of the stomach. After 24 hours 
erosions with a red base and petechia were seen in the same portion of 
the stomach, mainly on the greater curvature. After 48 hours larger 
erosions (2 to 25 mm. in diameter), which were slightly deeper with a 
dark base were seen. These were situated more distally, but still 
within the corpus. Damage limited to the antrum was not observed. The 
three patients who did have erosions in the antrum also had multiple 
lesions in the proximal area of the stomach. In the patients who had 
recurrent bleeds, the erosions remained throughout 3 weeks. On the 
other hand in patients who were recovering the erosions became more 
superficial, the base changed in colour from black to red and finally 
a completely normal mucosa was seen. The predilection for the corpus 
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of the stomach was confirmed by Stremple et al (3) in 14 patients with 
major trauma and gastrointestinal bleeding. Solitary ulcers were never 
seen, all patients had multiple (mainly 3 to 6) ulcers with a mean 
diameter of 1 em. One ulcer had penetrated deeply into the muscularis 
propria. In all investigated patients with a bleed a large artery was 
seen in the base of an ulcer. In addition to the ulcers, multiple 
erosions were seen. These authors described the ulcers as lying 
between the gastric mucosal folds. An explanation for the development 
of stress ulcers in the proximal portion of the stomach with sparing 
of the antrum, is given in chapter 3. 
The concept of stress ulcers should not be limited to the stomach 
(5). In the seriously ill patient the small and large bowel can also 
be involved. Stremple et al (3) found extensive hemorrhagic necrosis 
of the stomach and multiple ulcers in the small bowel in a patient 
with a gunshot wound of the chest and the thoracic spine. At operation 
they also found duodenal ulcers which, in view of the description -
ulcer craters with raised, firm edges - were probably preexistant and 
should be regarded as chronic rather than acute ulcers and therefore 
not as stress ulcers. Of greater importance is the fact that they 
found lesions in the colon of 8 patients; in 5 of these there was 
simultaneous gastroduodenal ulceration. Lucas et al (6) found 
hyperemic 
patients 
areas at 
also had 
endoscopy of the small 
acute erosive gastritis. 
and large bowel. These 
The duodenum and the 
terminal ileum appeared to be the most susceptible parts of the small 
bowel for stress lesions (7). Isolated or confluent red (hyperemic) 
areas can progress into mucosal ulcers which are small, superficial 
and of irregular form. Perforation is rare. The mesenteric arteries 
are open and there is no relationship between the position of the 
lesions and the topography distribution of the abdominal arteries 
(8,9,10). The risk factors for the development of lesions in small and 
large intestine, described in the literature, are the same as those 
for stress ulcers in the stomach, except for jaundice. Heart disease 
has been cited as an additional risk factor (8,9,10). 
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2.2 MICROSCOPY 
The stress ulcer (or erosion) is characterized histologically by 
loss of the surface epithelium, with loss of cells which can continue 
into the submucosa and occasionally into the muscularis propria. There 
is edema and hemorrhage (3 ,4). In the immediate vicinity there is 
usually some acute inflammatory infiltration (4,11). In Fig.l a stress 
erosion is shown. 
Fig.l. Cross section of the gastric mucosa with centrally located in 
this photograph a superficial mucosal defect. Underneath this 
erosion a dilated capillary vessel is seen (hematoxylin-eosin, 
60x). 
Typically there is no evidence for chronic inflammation (11). 
Lesions which are some days old, show a fibrinous exsudate and signs 
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of regeneration (1 ,3). Various changes may be seen in the adjoining 
blood vessels. Lucas et al (4) found no thrombosed vessels in the 
early stages of stress ulcers. Stremple et al (3) found in some 
patients organized thrombi in the submucosal vessels. Margaret ten et 
al (10) found in approximately two thirds of patients with hemorrhagic 
lesions in the digestive tract, on post mortem examination fibrin 
thrombi in the microcirculation of the mucosa and submucosa of stomach 
and intestine. These changes, taken together with changes in the 
clotting parameters, could be explained by diffuse intravascular 
coagulation. As mentioned above, Stremple et al found a large artery 
in the base of the ulcer in all patients with hemorrhage (3). This is 
in contrast to others who have postulated that hemorrhage is always 
derived from small, superficial vessels. 
Three dimensional topographic photography of the gastric mucosa has 
shown that in the early phase the apical membrane of the epithelia! 
cells is lost, with release of cell contents (4). When the cells are 
subsequently completely destroyed, erosions develop and fibrin bundles 
with entrapped erythrocytes are 
non-involved parts of the 
seen (4,5). In the macroscopically 
gastric mucosa, the cells are 
morphologically intact with normal mucus content of the mucus cells 
and, on electron macros copy, normal cell junctions are seen between 
epithelial cells (3,5). 
The microscopy of the gastric lesions is similar to that of the 
lesions in the small and large intestine (9). The destruction of cells 
is usua~ly limited to the mucosa, but can continue into the submucosa 
and occasionally into the muscularis propria. There is also edema and 
hemorrhage. Few inflammatory changes are seen, except in patients with 
l.esions of longer duration. Continuation of the process leads to 
replacement of the mucosa by a membrane composed of cell debris and 
fibrin. In general fibrin thrombi, emboli or obstructive arterial 
disease are absent. Margaretten et al have found fibrin thrombi in the 
microcirculation of the mucosa and submucosa, as described above (10). 
Levine states that the main characteristics are mucosal hemorrhage and 
thrombosis of the mucosal capillaries (8). Obstruction of larger 
vessels has not been described. 
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2.3 DIFFERENTIATION FROM OTHER ULCERS 
A. Ulcers occurring in patients with extensive burns (Curling's 
ulcers) are found either in the stomach, mainly in the fundus and 
corpus in the earlier phases (12 ,13) or in the duodenum in the 
later phase (13). Lesions are usually found in both the stomach and 
tb.e duodenum (12). The lesions in the stomach are multiple and 
superficial and have the macroscopic appearance of stress ulcers, 
but they sometimes progress to perforation (14). In the duodenum 
usually a solitary ulcer is found with histologically chronic 
inflammation and deep penetration into the submucosa and muscularis 
propria. Perforation is not uncommon. 
B. Ulcers occurring in association with cerebral or spinal column 
lesions (Cushing's ulcers) are to be found not only in the stomach 
but also in esophagus and duodenum (15,16). These ulcers are 
frequently deep with extensive necrosis and they often lead to 
perforation (15). 
C. A chronic peptic ulcer occurs at some stage in 5 to 10% of the 
population (17). Peptic ulcers are found four times more often in 
the duodenum than in the stomach (17). In the stomach peptic ulcers 
are to be found mainly in the antrum and on the lesser curvature 
and, in the duOdenum, most commonly in the duodenal bulb (18). 
Endoscopically these ulcers are usually solitary, and are often 
deep with a raised edge. Histologically, chronic inflammatory 
infiltrates are present with fibrosis. Penetration into the deeper 
layers and perforation are not rare. 
D. Ulcers and erosive gastritis caused by drugs such as aspirin and 
other non-steroidal analgetic and anti-inflammatory agents, and by 
alcohol form a separate entity. The lesions are morphologically 
identical to stress lesions, but they are localized mainly in the 
distal rather than the proximal part of the stomach (2,19,20). 
These four forms of ulcers must therefore be differentiated from 
stress lesions on the basis of both localization and histology. The 
pathophysiology of these lesions is also different, as will be 
described in the next chapter. 
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Chapter 3. 
Pathophysiology of stress ulcers 
3.1 INTRODUCTION 
In general stress ulcers and erosive gastritis are limited to the 
mucosa of the stomach and do not penetrate into deeper layers. In man 
mucosal changes can be detected within 24 hours of the development of 
the serious clinical condition (1). In animal experiments 
microscopical changes have been found in the mucosa of the gastric 
fundus within minutes of the onset of hemorrhagic shock; macroscopical 
lesions were visible within one hour (2). These lesions could also be 
induced in the terminal ileum and in the colon. 
It is an intriguing observation that the antrum of the stomach is 
very rarely involved. The acid producing portion of the stomach (the 
fundus and the corpus). is apparently more vulnerable. Although 
gastric acid plays a role in the development of stress ulcers. it is 
not clear whether this is the only or even the most important factor. 
Stress lesions in ileum and colon do not arise in an acid environment 
and stress ulcers have also been found in stomachs of patients with 
atrophic gastritis (2). The fundamental change is a rapid loss of the 
integrity of the gastric mucosal barrier under influence of the risk 
factors. 
In this chapter mucosal defense mechanisms will be described. The 
risk factors which predispose to stress ulcers are discussed. Stress 
ulcers do not develop as a consequence of only one of these risk 
factors. It is the combination of risk factors that is able to 
overwhelm the mucosal barrier. 
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3.2. GASTRIC MUCOSAL BARRIER 
A precise description of the gastric mucosal barrier, which forms 
the boundary between the highly acidic, pepsin containing fluid in the 
stomach and the vulnerable cell layer, '· 1S difficult to give. A 
hydrogen ion-gradient is maintained from pH 2 to 3 (lumen) to pH 6 to 
8 (cell surface). The gastric mucosal barrier can therefore 
be defined as the factors that prevent back-diffusion of secreted 
hydrogen ions. Davenport (3), who has investigated extensively 
situations where back-diffusion of hydrogen ions occurs, considered 
the gastric mucosal barrier to be mainly determined by the tight 
junctions between cells. He ascribed the back-diffusion of acid under 
influence of salicylates to an increased permeability of the mucosa, 
and suggested that the mucosal damage developes from this 
back-diffusion. However it is difficult to accept that the gastric 
mucosal damage is directly dependent on the back-diffusion of a 
certain amount of acid, as specified amounts of acids diffusing back 
within a certain time will give rise to mild damage in the presence of 
aspirin but no damage in the absence of aspirin (4, 5). In other 
studies it has not been possible to demonstrate back-diffusion of acid 
in experimental shock (6,7,8). 
Ki vilaakso et al (9) considered the low intramural pH of the 
gastric mucosa in shock to be mainly due to a decreased acid secretion 
in shock. The question of decreased acid secretion versus 
back-diffusion of secreted acid has not been solved (6). Aspirin, 
other non-steroidal anti-inflammatory drugs, bile acids, alcohol and 
hypertonic salt solutions all cause morphological changes in the 
gastric mucosa- namely loss of epithelial cells (10). That this loss 
·of epithelial cells is associated with back-diffusion of acid into the 
mucosa is not surprising. The gastric mucosal barrier can also be 
regarded as the epithelial layer of the gastric mucosa (6), and damage 
to the mucosal barrier as loss of this cell layer or at least loss of 
the apical membrane of these cells with or without maintenance of the 
tight junctions (11). 
Apart from influx of hydrogen ions this is associated with efflux 
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of sodium and potassium ions and organic material and hydrogen ions 
from the parietal cells. 
3. 3 MUCUS LAYER 
The gastric mucosa under normal physiological circumstances is 
covered by a layer of mucus, which consists of 2/3 glycoproteins and 
approximately 1/3 free proteins (12). 
The mucus is produced by the superficial epithelial cells and the 
neck cells, and is released mainly by exocytosis and apical expulsion 
and also by exfoliation of the older cells (13). Little is known about 
the regulation of mucus production (14). Mucus thickness is difficult 
to measure and the relationship between intracellular mucus, the mucus 
gel on the mucosa and the free mucus present in gastric juice 
(dissolved mucus) is not clear. A low intraluminal pH is associated 
with a greater amount of free mucus (14). Carbenoxolone and 
prostaglandins facilitate the apical expulsion of mucus (15). Urea 
causes dissociation of mucus (16). Aspirin decreases the thickness of 
the mucus layer, lowers the glycoprotein content of the gastric juice 
and interferes with the production of mucus in the cell (14). Aspirin 
acts on the apical ~xpulsion of mucus, probably to such an extent that 
the cell is exposed for prolonged periods to hydrogen ions and pepsin 
and is damaged after mucus depletion (15). As prostaglandins increase 
the apical expulsion of mucus, probably in a gradual fashion, and 
cause a thickening of the mucus layer (15,17) and increase the mucous 
content of the gastric juice (18), these compounds (19) appear to be 
of major importance for the mucus layer and mucosal protection. 
The rate of diffusion of hydrogen ions to the mucus gel is 
approximately four times slower than that through the unstirred water 
layer (20) . The mucus layer is therefore not a good barrier against 
acid. Large molecules, such as pepsin, cannot pass easily through the 
mucus layer (21). It is not clear how the still larger pepsinogen 
molecule passes through the mucus to the lumen. With micro-electrodes 
it has been shown that the pH of the mucus layer is approximately 7 
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on the epithelia! side, and approximately 2 on the luminal side 
(22,23). 
3.4 BICARBONATE 
The stomach is capable of producing bicarbonate (14). This is easy 
to demonstrate in the antrum, but more difficult in fundus and corpus, 
which are major acid producing areas (21). In the antrum bicarbonate 
is probably partly passively transported and in the fundus largely 
actively secreted (14). In animal experiments alkali production has 
been shown to be 5-10% of the maximal acid output (14). The alkaline 
secretion is diminished by anoxia and adrenalin and stimulated by 
gastric acid and probably also by stimulation of the vagus (14). 
Exogenous prostaglandins stimulate alkaline secretion (14,19,24). 
Aspirin and other non-steroidal anti-inflammatory agents decrease the 
secretion of bicarbonate, and this inhibition can be prevented by the 
prior administration of 16, 16 dimethyl-prostaglandin E2 (25). There 
is good evidence that the basal bicarbonate secretion is dependent on 
endogenous prostaglandin synthesis (14). 
3.5 MUCUS-BICARBONATE 
Mucus and bicarbonate individually cannot protect the gastric 
epithelium against gastric acid and pepsin. Mucus alone has little 
buffering capacity and has no anti-pepsin activity (14). A relatively 
small amount of bicarbonate by itself would be directly neutralized by 
the acid which is present in excess. However studies have shown that 
the mucus layer together with the bicarbonate appear to be capable of 
maintaining a pH gradient of approximately 2 on the luminal side to 
approximately 7 on epithelial side of the mucus layer (22,23,26), and 
thus to protect the gastric mucosa (Fig.1). The mucus gel is 
constructed in such a way that a small amount of penetrating 
hydrochloric acid is continually neutralized by bicarbonate coming 
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from the epithelial side. The mucus-bicarbonate-model implies a 
continuing secretion of bicarbonate. The pH on the epithelial side is 
increased by the administration of 16, 16-dimethyl-prostaglandin E
2 
and is decreased by aspirin and other non-steroidal anti-inflammatory 
drugs (21). Aspirin is indeed capable of destroying the whole pH 
gradient of the mucus layer within a few minutes (14). A very low 
intraluminal pH (lower than pH 1.4) also results in a lower pH 
gradient, so that the mucus bicarbonate barrier does not completely 
protect the cell layer against acid (14). 
3.6 MUCUS-BICARBONATE BARRIER IN RELATION TO ACID SECRETION AND 
CIRCULATION 
Gastric acid (hydrochloric acid, HCl) is secreted by the parietal 
+ 
cells in the gastric glands (Fig.l). Hydrogen ions (H) leave at the 
apical membrane of the cell. Intracellularly, bicarbonate (HC0
3
-) is 
formed, which passes across the basolateral membrane and is released 
into the intersti t~.um of the lamia propria (14). The intramural pH of 
the gastric mucosa is iDcreased in this way (46). Gastric mucosa which 
is actively secreting acid was shown to resist high concentrations of 
intraluminal acid better than resting mucosa (9,46). 
Gannon et al (27) described blood flow in the mucosal exchange 
vessels (capillaries) occuring only in a unidirectional fashion, from 
the serosal to the luminal aspect. They hypothesized a vascular 
transport of HC03-, released interstitially by secreting parietal 
cells, and taken away by fenestrated capillaries, from deep within the 
mucosa toward the gastric surface, thereby providing an optimal 
acid-base status for the superficial epithelial cells to secrete 
HC03-, or for the neutralization of back-diffusing H+ HC03- is 
secreted into the mucus layer, which is formed by superficial 
epithelial cells and by mucus cells in the gastric glands. Continuous 
secretion of HC03- maintains a pH gradient across the mucus layer. 
These aspects are shown schematically in Fig.l. 
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Supe.-ficial mucous 
cells 
Gast.-lc pit -------~3--,-11 
Fig.l. Schematic diagram of the gastric mucus-bicarbonate barrier, 
and proposed relation to acid secretion and capillary 
circulation. 
3.7 GASTRIC ACID AND PEPSIN 
Many authors have stated that acid and pepsin are necessary for the 
development of stress ulcers (7,8,16,28,29). However stress ulcers are 
also seen in the absence of acid, notably in the small and large 
bowel. Prophylactic administration of antacids or 
histamine-2-receptor-antagonists do not result in complete prevention 
of bleeding from the upper gastrointestinal tract (30,31,32,33,34). In 
general, acid production is not increased in patients under stress, 
and in the first days after onset of the stress situation acid 
secretion is often decreased (16,35,36). An increased gastric acid 
secretion develops during prolonged stress, after several days 
(1,36,37). The role of gastric acid in the development of stress 
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ulcers therefore is still not clear (2). The early decrease in acid 
production occurs at the same time as a decrease in blood flow through 
the gastric mucosa, which has been regarded as being a major factor in 
the development of acute mucosal lesions (6). The mucosal lesions 
caused by ischemia and other risk factors can in second instance 
become larger and deeper by the actions of acid and pepsin. 
3.8 GASTRIC MUCOSAL BLOOD FLOW; THE ROLE OF HYPOTENSION 
Mucosal ischemia appears to be the most important factor in the 
development of stress ulcers (6,16,35,38). Shock results, by the 
sympathetic nervous system, in constriction of the splanchnicus blood 
vessels. The effect of adrenalin on intestinal blood flow in shock and 
stress is not always inhibitory, the alpha-effect being 
vasoconstriction and the beta-effect being vasodilation (39). In 
experimental animals in general a decreased mucosal blood flow is 
necessary for the development of stress ulcers (16,38). An increased 
mucosal perfusion caused by intra-arterial infusion of isoprenaline 
can prevent gastric ulcers in dogs with hemorrhagic shock (40). In 
clinical situations stress lesions often develope in patients in whom 
the gastric mucosal blood flow has been reduced for only a brief 
period. Ischemia can give rise to mucosal lesions within in relatively 
short period (some hours) (1,37). The mucosal blood flow of the 
stomach can theoretically be circumvented by submucosal arteriovenous 
anastomoses, but there is still some discussion whether such 
anastomoses exist (27,41). Decreased mucosal blood flow results 
initially in an energy deficit, but eventually causes cell necrosis. 
Shortage of oxygen interferes with adenine nucleotide metabolism (2). 
Menguy and co-workers (42) showed in rats that hemorrhagic shock 
resulted in a greater lowering of adenosine triphosphate (ATP) in the 
gastric mucosa than in the liver or skeletal muscle. Energy metabolism 
of the gastric mucosa is therefore much more sensitive to ischemia 
than the liver or skeletal muscle, possibly due to the relatively 
lower glycogen level. These authors demonstrated a lesser decrease in 
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the ATP concentration in the antrum of rabbits than in the corpus or 
fundus of the stomach (2, 43). In these experiments with rats and 
rabbits corrections were made for possible local differences in blood 
flow. In addition the authors found that hemorrhagic shock following 
fasting resulted in larger stress lesions and lower ATP levels than in 
the post-prandial situation (44). Low ATP levels were also found in 
the small bowel following shock and especially in areas where ulcers 
first develop, namely the duodenum and the terminal ileum (2). ATP 
shortage reduces the activity of the sodium pump and at a certain 
level more sodium ions and water will enter the cell, resulting in 
cell death (2). 
The findings of Menguy and co-workers appear to provide a better 
explanation for the development of stress ulcers than those of Silen 
and co-workers (6,28), who ascribed the consequences of mucosal 
ischemia to the development of a low pH in the mucosa due to increased 
back diffusion of hydrogen ions and a decreased buffering capacity for 
acid in the gastric mucosa. Silen and co-workers postulated that this 
lowering of intramural pH, which not only comes from back-diffusion of 
hydrogen ions but also by a decreased venous removal of hydrogen ions 
and a decreased arterial supply of bicarbonate, taken together with 
the associated systemic acidosis, results in loss of mucosal areas. 
Increased intraluminal hydrogen ion concentrations results in an 
increase in blood flow through the gastric mucosa (45) so that the 
intramural pH does not decrease. However above a certain hydrogen ion 
concentration the perfusion does not increase further and intramural 
.pH can decrease. The buffering bicarbonate is also supplied by 
actively secreting parietal c?.lls (22). The histamine stimulated 
stomach is more resistent to ulceration than the metiamide inhibited 
stomach (46), which could be related to the high and/or low hydrogen 
ion concentration in the gastric mucosal cell. These theories, 
however, do not explain why back diffusion of hydrogen ions should 
increase in stress. 
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3.9 UREMIA 
Stress ulcers in uremia develop mainly in the corpus of the stomach 
but also in the duodenum (47). Fifteen-30% of the circulating urea 
diffuses into the gastrointestinal lumen (47). In patients with uremia 
a raised urea level has been found in gastric juice and it has been 
shown that high concentrations of urea can dissolve human gastric 
mucus (48). Urea in high concentrations also causes direct damage to 
the superficial cells of the stomach without dissolution of the tight 
junctions (49). Cronic renal failure is often accompanied by various 
forms of gastric lesions, which can not always be differentiated from 
stress lesions. Stress ulcer may develop in patients suffering from 
renal failure together with other risk factors. 
3.10 BILE ACIDS 
In severely ill patients biliary reflux from the duodenum into the 
stomach is often seen, caused amongst other things by paralytic ileus. 
Closure of the pylorus decreases the development of gastric ulcers in 
dogs subjected to hemorrhagic shock, and stress ulcers can be provoked 
by administration of taurochlorate into the stomach (50,51). 
Martin and co-workers (52) showed that bile salts are capable of 
changing the physical characteristics of the mucous layer. Damage to 
the superficial cells of the stomach by bile salts occurs despite an 
intact tight junction (49). Although an increased back-diffusion of 
hydrogen ions following the effect of bile has often been suggested 
(9 ,10, 53). the back-diffusion appears to be more the result of the 
lesions caused by bile salts than the cause of the lesion. Bile salts 
have differing effects at differing pH levels (9,54), depending on the 
PKa. Taurochlorate (PKa 1.8), for example, only damages an intact 
stomach at a low intraluminal pH. Deconjugated bile salts and 
dihydroxy bile salts give rise to more mucosal lesions than do 
conjugated bile salts and trihydroxy bile salts (55). Deconjugated 
bile salts however, precipitate at low pH and become inactive because 
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their PKa is higher than 5 (9,54). 
Ritchie (55) performed a series of elegant studies in dogs in which 
he showed that gastric mucosal lesions only developed in the presence 
of the combination of acid, bile salts and mucosal ischemia. He also 
studied intensive care patients and showed that this combination of 
factors is necessary for the development of gastric lesions in humans, 
and that in patients bile salts also play a role. He was able to 
demonstrate an increased gastric mucosal blood flow following exposure 
of the gastric mucosa to bile salts at a low pH, and that the blood 
flow was directly related to the hydrogen ion back-diffusion. 
In practice it is important to know that bile salts in 
physiological concentrations and at low pH (that is below the PKa of 
the toxic bile salts) can give rise to gastric lesions in the presence 
of mucosal ischemia. This is in agreement with the clinical 
observation that stress lesions often are seen shortly after gastric 
juice with a low pH becomes bile tinted (56). Probably, biliary reflux 
into the stomach in combination with one or more risk factors - and 
not only mucosal ischemia - can lead to stress ulcer formation. 
3.11 JAUNDICE 
In the most extreme example of jaundice, namely acute liver 
insufficiency, upper gastrointestinal bleeding occurs in approximately 
50% of patients (57). 
Skillman and co-workers (58) and Lucas and co-workers (1) already 
regarded jaundice as a risk factor. The manner in which jaundice 
promotes the development of stress ulcers is not clear. It is possible 
that the mechanism is related to the associated disturbances in 
clotting, which exacerbate bleeding from erosions or ulcers resulting 
from other risk factors (57). 
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3.12 SEPSIS AND PERITONITIS 
As not every sepsis is associated with shock, stress ulcers in 
septic patients can not always be explained by hypotension. 
Le Gall and co-workers (59) showed endoscopically that sepsis by 
itself could give rise to stress ulcers in intensive care patients. 
Sepsis is often associated with a hyperdynamic circulation, and this 
should not necessarily be associated with a decrease in gastric blood 
flow. In septic animals an increased blood flow to the stomach, 
including the gastric mucosa, has indeed been observed (56). Sepsis, 
like shock, probably causes a redistribution of blood flow to the 
detriment of the subepithelial capillaries of the gastric mucosa, 
resulting in epithelial hypoxia (60). Little is known about the role 
of endotoxins in the development of stress ulcers. Sepsis often causes 
hypofibrinogenemia, thrombocytopenia and thrombocytopathy, which can 
increase or prolong blood loss. Sepsis complicating shock or trauma 
causes a marked increased risk of stress ulcers developing (56) . In 
general gram negative bacteria are involved (36). The chance of stress 
ulcers developing is also dependent on the source of the sepsis: 
intraperitoneal and pulmonary infections result in a greater chance of 
stress ~leers than cellulitis, phlebitis and soft tissue abcesses (56). 
3.13 RESPIRATORY INSUFFICIENCY 
Bleeding from stress ulcers occurs in approximately 20% of patients 
with respiratory insufficiency, and the incidence is much higher when 
adult respiratory distress syndrome is the cause of the respiratory 
insufficiency (61). The mechanism for the development of stress ulcers 
is probably tissue hypoxia (34) together with an increased gastric 
acid production (61). 
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3.14 MAJOR OPERATIONS AND MULTIPLE TRAUMA 
The extent and duration of the operation and severity of trauma are 
directly related to the risk of developing stress ulcers and stress 
bleeding (36). Both are often associated with paralytic ileus (62). 
The majority of the patients described by Beil and co-workers (63) 
with postoperative hemorrhage had associated infections. Fogelman and 
co-workers (64) described acute gastrointestinal ulceration after 
operational trauma in a group of patients with whom more than the half 
were septic. Lucas and co-workers (1) found within 24 hours gastric 
lesions in all patients with major trauma. In these patients there was 
often associated sepsis, renal insufficiency or jaundice. Gastric acid 
product ion is in general reduced in the first 2 to 3 days after 
trauma, but thereafter it is increased with a raised pepsin, protein, 
DNA and sialic acid content of the gastric juice (65,66). Temporary 
hypotension appears to play the greatest role in the pathogenesis of 
stress ulcer both following trauma as well as following major 
operations. 
3.15 CORTICOSTEROIDS 
Patients treated on an intensive care 
corticosteroids. These could theoretically play 
are often 
a role in 
given 
the 
development of stress ulcers. The effect of corticosteroids on gastric 
mucosa is a controversial area. Both harmful (67 ,68) as well as 
favourable (69) effects have been described. Conn and Blitzer (70) in 
a large study were unable to find a clear relationship between 
corticosteroid treatment and peptic ulcers. A favourable effect of 
corticosteroids could theoretically be derived from lysosomal 
stabilisation (71) and deleterious effects of corticosteroids are 
exemplified by delayed healing of peptic ulcers and reactivation of 
existing duodenal or gastric ulcers (72). Whether corticosteroids 
promote the development of stress ulcers is not known. Corticosteroids 
inhibit the enzyme phospholipase. which converts phospholipids into 
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arachidonate 
Prostaglandins 
gastric mucosa 
maintenance of 
and other 
are present 
(74, 75) and 
precursors of 
in relatively 
they play an 
gastric mucosal integrity 
prostaglandins (73). 
high concentrations in 
important role in the 
(75,76). Theoretically 
therefore corticosteroids could facilitate the development of stress 
ulcers by prostaglandin depletion. 
3.16 PROSTAGLANDINS 
Prostaglandins protect the stomach against the damaging effects of 
aspirin, alcohol, hydochloric acid, sodium hydroxide, hypertonic salt 
solutions and heat (77,78). Prostaglandins also decrease acid 
production (78). However they protect against damaging substances at 
dosage levels which do not decrease gastric acid secretion (75). This 
effect has been called cytoprotection (76,79), a concept which will be 
discussed further in the next chapter. Risk factors, such as 
hypotension, could cause a deficiency of prostaglandins, whereby the 
gastric mucosa is incapable of withstanding the effects of acid and 
pepsin, thus leading to the development of stress ulcers. 
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Chapter4. 
Prostaglandins: gastrointestinal effects and 
cytoprotection 
4.1 INTRODUCTION 
Prostaglandins (PGs) are synthesized in all nucleated cells of the 
body. These biologically active substances are thought to be local 
regulators of cell and tissue functions rather than circulating 
hormones. Only small amounts of PG are found extracellulary, as they 
are unstable and are also rapidly broken down by local enzymes. 
4.2 CHEMISTRY 
PGs are derivatives of polyunsaturated fatty acids, in humans 
mainly of arachidonate. The chemical structure of PGs is characterized 
by a cyclopentane ring connected with two fatty acid chains; one of 
these chains has a terminal carboxyl group. PGs are called A, B, C, D, 
E, F according to their substi tuents at the cyclopentane ring. The 
suffix 1 or 2 or 3 indicates the number of double bonds in the fatty 
acid chains, e.g. PGE2 . In addition, alpha or beta can be added to 
indicate the stereometry of the hydroxyl group at the c 9 position of 
the ring, e.g. PGF 2alpha 
4.3 BIOSYNTHESIS AND DEGRADATION 
PGs are synthesized by membrane bound enzymes. Polyunsaturated 
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fatty acids are used as a substrate. These are obtained as essential 
fatty acids in food and are stored in the membranes as phopholipids. 
The enzyme phospholipase A2 hydrolyzes these phospholipids at the 
membranes, and the released arachidonate is metabolized by a 
microsomal enzyme called cyclooxygenase, to endoperoxides. The 
endoperoxides are the precursors of PGs and also of prostacyclin and 
thromboxanes. 
In mammals PGE2 and PGF2alpha are quantitatively the most important 
prostaglandins. PGs are not stored but are used immediately after 
their synthesis. Most PGs are stucturally unstable. They are rapidly 
degraded by enzymes. If PGs of the E or F group enter the circulation 
they are catabolized rapidly by enzymes in the liver and the lungs, 
usually in a single passage. Degradation is mainly by oxidation of the 
c15 group, followed by reduction of the double bond between c 13 and 
c14 (1). 
4.4 INHIBITION OF SYNTHESIS 
Acetylsalicylic acid and other nonsteroidal antiinflammatory drugs 
(NSAIDs) such as indomethacin inhibit PG synthesis by selective 
inhibition of cyclooxygenase. Their action is detectable within one to 
ten minutes (2). 
Corticosteroids inhibit PG release by inhibition of the enzyme 
phospholipase. This effect can be seen only after several hours or 
sometimes days of treatment, because the action is via newly 
synthesized proteins (2). 
4.5 GASTROINTESTINAL MOTILITY 
PGs act on smooth muscles of the whole gastrointestinal tract (3). 
In general, longitudinal muscle is contracted byE and F PGs. Circular 
smooth muscle is relaxed by E series and contracted by F series PGs. 
PGs cannot be called neurotransmitters but they modulate and modify 
36 
synaptic function. PGE1 and PGE2 , when administered exogenously, relax 
the lower esophageal sphincter. The oral administration of PGE in man 
was found to be associated with reflux of bile into the stomach, due 
to relaxation of the pyloric sphincter (4,5). Gastric emptying is not 
markedly affected. PGE can induce diarrhea as a result of increased 
motility and accelerated intestinal passage (6). The small intestine 
is the sj. te of the described responses (3) and diarrhoea limits 
clinical applications of PGs. The release of PGs is increased by 
intestinal muscle contraction. Indomethacin, which acts as a PG 
synthesis inhibitor, diminishes colonic muscle activity (7). This 
suggests a possible role for PGs in modulating colonic motility. 
4.6 EFFECTS ON GASTRIC SECRETION 
PGE1 , PGE2 , PGA1 and PGA2 inhibit gastric acid secretion (8,9). 
Naturally occuring PGs, when administered orally, have no or at most a 
very small inhibitory effect on gastric acid secretion (8,9). 
These PGs are metabolized by the gastrointestinal tract and 
inactivated by the liver and the lungs following absorption. 
Parenteral administration of PGs results in a marked reduction of 
gastric acid secretion. Synthetic analogs of PGs, such as 
16,16-dimethyl PGE2 and 15(R)l5-methyl PGE2 have been shown to be more 
potent inhibitors and their effectivity is not lost by oral 
administration (3,8,9). 
PGs decrease gastric secretion volume as well as total acid output, 
the effect on acid output being greater than that on volume. Total 
pepsin output diminishes parallel to reduction of gastric secretion 
volume. Natural PGE2 has been found in man to decrease gastric acid 
secretion when given intravenously (10), while no effect could be 
shown using the oral route (9, 11) . Recently however, Reele and Bhan 
(12) described inhibition of liquid protein meal-stimulated gastric 
acid secretion in man, following oral administration of PGE2 . This 
effect was seen with dosages of 1.0 mg and more. Another study 
confirmed this effect of natural PGE2 during vagal stimulation of acid 
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production (13). 
The mechanism by which PGs inhibit acid secretion is probably by a 
direct effect on parietal cell (3,14). Soll and co-workers observed an 
inhibitory effect of PGs on the histamine-mediated stimulation of 
adenyl cyclase and on production of cAMP in parietal cells (15 ,16). 
PGs seem to have a physiological role in modulating gastric acid 
secretion (13). 
4.7 EFFECTS ON INTESTINAL SECRETION 
PGE stimulates the secretion of water and electrolytes from the 
jejunum (3). The cholera toxin acts in a similar way (3). PGE2 
mediated secretory diarrhea from a villous adenoma has been reported 
(17). 
4.8 EFFECTS ON PANCREAS AND BILE SECRETION 
Inhibition as well as stimulation by PGs of cholecystokinin-
stimulated exocrine pancreatic secretion has been reported (3). 
PGE 1 and PGA1 probably increase the bile flow in the dog (3). 
4.9 CYTOPROTECTION 
Cytoprotection was originally defined as the ability of PG to 
protect the gastrointestinal ~pi thelium against potentially noxious 
agents, which otherwise would cause necrosis (18,19,20). This 
protective effect is not dependent on inhibition of gastric acid 
secretion, as cytoprotection can be shown with dosages too low to give 
such inhibition. The studies and publications of Robert have made this 
cytoprotective effect of PG well known (19,20,21). He found, for 
example, that PGs protected against absolute alcohol, concentrated 
solutions of hydrochloric acid and of sodium hydroxide, hypertonic 
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sodium chloride and thermal injury in rats (21). 
Gastric cytoprotection is rapidly achieved. When given orally one 
minute before administration of absolute alcohol, PGs reduce the 
number and the severity of gastric lesions by 80%. When given two 
minutes before ethanol the protection is complete. The protection 
lasts approximately 2 hours after administration of PGE2 (22). 
In a recent publication Robert et al (23) pointed out that part of 
the gastric mucosa is not protected, i.e. the monolayer epithelium 
which covers the mucosa. Robert was prompted to change the definition 
of cytoprotection, which is now "the property of certain PGs to 
protect gastric mucosal tissue located under the surface epithelium 
from becoming hemorrhagic and necrotic after exposure to noxious 
agents" (23). 
Cytoprotection by PGs is also demonstrated in the prevention of 
gastrointestinal ulceration induced by NSAIDs and corticosteroids 
(20,24,25,26,27). Evidence of this cytoprotective effect has been 
shown in animals (24,26) and in man (25,27,28). A protective action by 
PGs against taurochlorate-induced gastric hemorrhage in rats has also 
been reported (26). 
4.10 MECHANISMS OF CYTOPROTECTION 
Although the exact mechanism of cytoprotection is not known, some 
facts have emerged. First, orally and topically administered PGs have 
a three to five fold more powerful cytoprotective action than 
parenterally administered PGs (21). Secondly, PGs act immediately, 
i.e. their maximal cytoprotective effect is reached within one minute 
(21). 
There is evidence for the following mechanisms in cytoprotection: 
1. Stimulation of bicarbonate secretion (29); 
2. Stimulation of mucus secretion (30); 
3. Increase of mucosal blood flow (32); 
4. Stimulation of the sodium transport from mucosa to serosa (33) and 
of gastric chloride transport (34), together with an increase in 
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electrical potential difference of the mucosa (35); 
5. Increase of mucosal coating with phospholipids (36); 
6. Lysosomal stabilization (37); 
7. Stimulation of intracellular cyclic AMP (33,37). 
Mucosal penetration of noxious agents is not prevented by PGs (22). 
PGs therefore seem to act at cellular level, and luminal factors are 
probably less important than intramucosal processes. As was shown by 
Tarnawski et al (38), PGs protect the mucosal proliferative zone, from 
which rapid migration of cells toward the luminal surface follows 
injury by alcohol. Microscopic lesions may be seen after ethanol 
despite PG-pretreatment, but cells in the gastric pit base are spared, 
and reepithelialization is detectable within 60 minutes (39). 
Therefore in studying cytoprotection not only should 
macroscopically detectable mucosal lesions be taken into account, but 
also light microscopical and electron microscopical lesions (37). 
Cytoprotection should always be defined histologically (40). 
4.11 ADAPTIVE CYTOPROTECTION 
Mildly irritating substances have a cytoprotective action against 
necrotizing agents, if they are administered prior to the necrotizing 
agent (41). For instance, in rats a ten percent alcohol solution given 
intragastrically protects against subsequent instillation of absolute 
alcohol. This effect develops within 15 minutes. Pretreatment with 
certain mildly irritating substances also has a cytoprotective effect 
against necrotizing agents with a quite different chemical structure 
(37). Indomethacin blocks this adaptive effect, thus providing 
evidence for a PG mediated mechanism (37). Intragastric administration 
of a mildly irritating agent results in an increased synthesis of PGE2 
and other PGs in the gastric mucosa, especially in the corpus (41). 
Adaptive cytoprotection seems to be a normal physiological mechanism, 
mediated by PGs. 
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4.12 PROSTAGLANDIN RECEPTORS IN GASTRIC MUCOSA 
Tepperman et al (42) provided evidence for a specific binding site 
with high affinity for PGE2 in the porcine gastric mucosa. They found 
a much higher affinity in the fundus than in the antrum of the 
stomach, which itself had higher affinity than the esophagus, 
duodenum, ileum or colon (43). 
4.13 CLINICAL APPLICATIONS OF PROSTAGLANDINS IN GASTROENTEROLOGY 
In the mouse PGE2 has a protective effect on diet-induced 
pancreatitis (44). Investigations in man have shown some beneficial 
biochemical effects of PGE2 in acute pancreatitis, given in a dose of 
0.1 mg/kg body weight per 24 h intravenously (45). 
Sepsis-induced gastric erosions can be prevented in dogs by 
16 ,16-dimethyl PGE2 , with dosages not inhibiting gastric acid 
secretion, as was shown by Odonkor et al (46). Other animal 
experiments using PGs showed the prevention of the restraint ulcer 
(47) exertion ulcers (48) and shock-induced ulcers (47). These 
findings suggest a possible use of PGs in critical care medicine. 
Natural PGE2 , in a 1 mg four times daily dosage, can prevent 
gastrointestinal blood loss induced by aspirin in man (28). A 1 mg 
three times daily dosage has the same protective effect against 
indomethacin (49). For these applications PGE2 should be given before 
or simultaneously with NSAIDs. Endoscopic studies showed the 
prevention of aspirin-induced gastroduodenal lesions by 15(R)15-methyl 
PGE2 (arbaprostil) and by enprostil, which are synthetic analogs of 
PGE2 (25,50). 
Healing of active duodenal ulcer is promoted by PGE2 at a dosage of 
0.5 mg three times daily, without concomitant reduction in gastric 
acid secretion (11). Arbaprostil accelerates the healing of duodenal 
ulcer, but has also a significant inhibitory effect on gastric acid 
secretion (51). This ulcer healing effect cannot be explained by 
changes in basal or meal-stimulated serum gastrin, as was shown by 
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Tytgat and Huibregtse (52). Gastric ulcer healing too, is facilitated 
by treatment with PGE2 analogs (53,54). 
Some case reports have been published in which stress bleeding was 
stopped using 15(R)l5-methyl PGE2 , after treatment failures with 
different other drugs (55,56). Long term treatment with 15(R)15-methyl 
PGE2 leads to an increased thickness of gastric mucosa via decreased 
exfoliation of mucus cells (57). 
From the gastric-protective effects of PGs in animals and man 
described above, one could expect a beneficial effect of PGs in the 
prevention of stress-induced ulcers. In the next chapter a clinical 
trial is described, which was aimed to test the clinical usefulness of 
PGE2 in the prophylaxis of stress-induced ulcers. 
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PREFACE TO CHAPTER 5. 
In this chapter a clinical trial on the prevention of 
gastrointestinal bleeding in Intensive Care Unit (ICU) patients is 
described. 
Two or more risk factors were taken as an inclusion criterion as 
bleeding in patients with only one risk factor is rare (1 ,2). Three 
days' duration of the study was assumed to be a minimal prerequisite 
for adequate evaluation, as stress bleeding is rarely seen within 48 
hours after the onset of a serious clinical condition (3) and ulcer 
formation takes at least 48 hours ( 4). The observation period was 
arbitrarily extended over seven days, mainly for practical reasons. 
Stress bleeding prophylaxis is basically aimed at preventing stress 
ulcers and erosions. Theoretically, we should do endoscopies at 
regular intervals to document these lesions. However, this can hardly 
be accomplished for practical and ethical reasons. Assuming that blood 
loss is a feature of mucosal injury, we determined blood contents in 
gastric aspirates, using the 51chromium (51Cr) method. Although colour 
tests, based on the peroxidase reaction, such as the guaiac and 
orthotolidine test, have been used, these tests are semiquantitative 
and are intended for the determination of blood in faeces and urine, 
rather than in gastric juice. As we had chosen an indirect parameter, 
i.e. blood loss instead of endoscopy, we needed an accurate test for 
51 determination of blood loss. So we prefered the Cr-method, which is 
generally accepted to be the best quantitative test for blood loss 
(5), although it is more laborious than colour test strips. Previous 
work at our department (6) had shown that most ICU patients had less 
than 5 ml blood loss per 24 h, while another small group of patients 
had more than 15 ml blood loss per 24 h. Therefore we took more than 
15 ml blood loss as a criterion of bleeding and as evidence of mucosal 
injury. 
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Chapter 5. 
Intragastric prostaglandin E 2 and the prevention 
of gastrointestinal hemorrhage in ICU patients 
5.1 ABSTRACT 
The effects of intragastric prostaglandin E2 (PGE2) on the 
occurrence of acute gastrointestinal hemorrhage in intensive care 
patients were investigated in a prospective, double-blind, 
placebo-controlled study. Ninety patients with two or more risk 
factors (major surgery, multiple trauma, respiratory insufficiency, 
renal insufficiency, jaundice, hypotension, peritonitis, sepsis) were 
randomized for treatment with either prostaglandin E2 (0. 5 mg) or 
placebo, administered every 4 h via 
gastric aspirates was measured by 
a nasogastric tube. Blood loss in 
51 Cr-erythrocyte labeling and a 
peroxidase test (orthotolidine). Of 57 patients, who could be 
evaluated, 29 received PGE2 and 28 received placebo. Hemorrhage 
occurred in nine PGE2 patients and 13 placebo-treated patients, not a 
significant difference. The occurrence of hemorrhage was related to 
the number of risk factors, and gastrointestinal hemorrhage was rarely 
the major factor determining mortality. Results of the orthotolidine 
test were not positively correlated with those of erythrocyte 
labeling, indicating that peroxidase tests should not be relied upon 
to detect blood in gastric aspirates. 
5.2 INTRODUCTION 
Acute gastrointestinal bleeding from stress ulcers can be 
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life-threatening in severely ill patients. Factors which promote the 
development Of stress ulcers a:re: respiratory insufficiency, 
hypotension, sepsis, peritonitis, renal insufficiency, major surgery, 
1-3 
major trauma, and jaundice. Stress ulcers are often multiple, 
localized in the corpus or fundus of the stomach, and do not penetrate 
beyond the submucosa; they may be preceded or accompanied by erosions. 
2,4 
Extensive burns, and/or brain damage can be accompanied by bleeding 
5 6 from a different type of ulcer. ' In contrast to stress ulcers this 
ulcer is usually solitary and is found not only in the stomach but 
also in the esophagus and duodenum. It is often deep and perforation 
may occur; thi's ulcer probably has a different pathophysiology from 
the stress ulcer. 
The reported incidence of stress ulcer varies; endoscopic evidence 
of stress lesions has been found in 100% of patients suffering acute 
2 trauma, and 5% to 20% of ICU patients may develop a gastrointestinal 
bleed. 1,7,8 Clinically manifest bleeding from a stress ulcer 
9 
.accompanied by a mortality of more than 30%. 
is 
The role of gastric acidity in the development of stress ulcers is 
not completely clear. 10- 13 The incidence of bleeding from the upper 
gastrointestinal tract in ICU patients can be reduced by titrating the 
. . 14 . 8 10 11 15 gastric contents w~th antac~ds ; however, several stud~es ' ' ' 
have failed to show a beneficial effect of cimetidine in the 
prevention of stress bleeding. 
The integrity of the gastric mucosa is adversely affected by the 
risk factors for stress ulcers, especially shock which leads to 
ischemia and anoxia. Prostaglandins play an important role in the 
maintenance of an intact gastric mucosal barrier. To examine the 
possible clinical applications of prostaglandins in the prevention of 
bleeding from stress lesions in ICU patients, we performed a 
prostective double-blind 
normally present in the 
study. Prostaglandin E2 (PGE2), which 16 gastric mucosa, was chosen as 
is 
the 
therapeutic agent. We used a dose which does not inhibit gastric acid 
production, so that any prevention of bleeding could be ascribed to 
cytoprotection rather than to decreased gastric acidity. 
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5.3 PATIENTS AND METHODS 
All patients admitted either to the surgical or medical ICU were 
considered for inclusion in the study. The criteria for exclusion 
were: previous esophageal or gastric surgery, the presence of 
esophageal varices or extensive burns, evidence of gastrointestinal 
bleeding on ICU admission, and expected discharge and/or expected oral 
feeding within 3 days. Eligible patients had two 
following risk factors for the development of stress 
or more of the 
14 
ulcers : major 
surgery; respiratory insufficiency, defined as need for artificial 
respiration; renal insufficiency, defined as serum creatinine level of 
more than 170 umol/L or an oliguria of less than 300 ml/day; multiple 
trauma; peritonitis, confirmed by laparotomy or ascites tap; 
hypotension, defined as a systolic blood pressure of less than 100 mm 
Hg for 2 h or longer, or cardiopulmonary resuscitation or hypotension 
requiring treatment with adrenergic agents and/or MAST (Medical Anti 
Shock Trousers); sepsis, defined as a positive blood culture or the 
combination of fever, hypotension, leukocytosis and an infective 
focus; and/or jaundice, defined as a serum bilirubin level of more 
than 80 umol/L. 
Patients were randomly assigned to receive placebo or prostaglandin 
therapy, in a double-blind fashion. Treatment was started within 24 
hours of ICU admission. Prostaglandin patients received 0.5 mg of 
prostaglandin E2 (PGE2 , Upjohn) dissolved in 20 ml of water. Placebo 
patients received only water. Both fluids were administered every 4 h 
via the gastric tube. After administration the tube was flushed with 
20 ml of water and clamped for 30 min. The clamp was then removed, and 
the gastric contents allowed to drain by gravity until the next PGE2 
or placebo administration. 
At the start of the study, before administering the first dose, a 
sample of gastric juice was obtained to determine pH, using a combined 
glass/calomel electrode (Metrohm E350B, Herisau). The gastric pH was 
remeasured every 24 h. In order to examine the effect of gastric 
acidity on the development of stress ulcers, we calculated the number 
10 14 
of days in which the pH was less than 3.5. ' 
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Gastric blood loss was qualitatively measured every 3.5 h by 
inspection for manifest hemorrhage and by a peroxidase test based on 
the ort·hotolidine reaction (Multistix), and quantitatively measured 
every 24 h by 51cr-chromate labeling of the erythrocytes. For 
51 Cr-chromate labeling, 10 ml of blood was withdrawn from the patient; 
the erythrocytes were then labeled with 30 uCi (1.11 MBq) of 
51
cr-chromate and readministered. 17 The collections of gastric juice 
were pooled daily and their radioactivity measured in a large-volume 
gamma counter (Armac 3002, Packard~ Brussels, Belgium). Ten ml of 
blood was withdrawn daily and used as standard. More than 15 ml of 
blood loss from the upper gastrointestinal tract was considered to be 
evidence of mucosal damage in the stomach. Clinically manifest 
bleeding was also regarded as evidence of mucosal damage. When 
possible, patients with either occult or manifest bleeding, underwent 
acute gastroscopy. 
The study lasted from 3 to 7 days. Treatment was discontinued if 
enteral feeding was given within the first 3 days, if the gastric tube 
was removed, if the patient was discharged from the ICU, if gastric or 
duodenal surgery was. required after the beginning of the study, or if 
the patient had a gastrointestinal hemorrhage following ICU admission. 
Fisher's exact test and the Chi-square test with Yates' correction 
were used for statistical comparisons of placebo and PGE2 groups. 
5.4 RESULTS 
Ninety patients were admitted to the study in the period November 1981 
to September 1983. Of these patients, three were excluded when 
retrospective evaluation indicated noncompliance with the entry 
criteria. Twelve other patients received enteral feeds or underwent 
gastric tube removal within the first 3 days. Eight patients were 
excluded because gastrostomy was performed within the first 3 days 
(one patient), no chromium labeling was performed (one patient), or 
ICU discharge was within the first 3 days (six patients). Finally, 
nine patients died within ~he first 3 days without signs of bleeding. 
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The remaining 58 patients complied with the requirements of the 
protocol. Of these, 29 received PGE2 and 29 were given a placebo. The 
two groups were similar with regard to sex distribution, age, and 
number and nature of risk factors (Table 1). 
Table 1. Patient characteristics 
Placebo 
Number of patients 29 29 
Sex ratio (men:women) 15:14 19:10 
Mean age (yr) 51,9 (17-80) 54,8 (18-78) 
Medical ICU 14 11 
Surgical ICU 15 18 
Mean number of risk factors 3.2 3.0 
Lesions causing hemorrhage were in the stomach, duodenum and/or 
esophagus. Hemorrhage occurred in nine (31%) of the 29 PGE2 patients 
and in 13 (46%) of the 28 placebo patients. In the PGE 2 group, 
hemorrhage was clinically manifest in four patients (three with 
51 hematemesis, one with melena) and detected by the Cr-method in five 
patients. In the placebo group, clinically manifest hemorrhage 
occurred in four patients (three with hematemesis, one with bloody 
stools via a colostomy), and hemorrhage was detected by the 
51
cr-method in nine. One other patient in the placebo gro'lP exhibited 
bleeding from a traumatic lesion in the pharynx, and this patient was 
therefore left out of the further calculations. The difference in 
frequency of hemorrhage between the PGE2 and placebo group was not 
statistically significant. The results of the orthotolidine reactions 
in a number of the same gastric 
results of the 24-h blood loss 
chapter 6). 
aspirates did not correlate with the 
51 
as measured by the Cr-method (see 
The patients with hemorrhage were treated with antacids (Regia-pH 
15 every 2 h) in the medical ICU, and with cimetidine sometimes 
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together with antacids in the surgical ICU. One PGE2 patient underwent 
a laparotomy for a gastric perforation after 18 days of cimetidine 
treatment. One placebo patient's bleeding duodenal ulcer was treated 
by electrocoagulation during gastroscopy. The overall mortality of the 
bleeding patients was high: eight of the nine PGE2 patients and seven 
of the 13 placebo patients died. In most patients death was due to the 
underlying disease and its complications and not to gastrointestinal 
bleeding. Patients with hemorrhage had more risk factors than patients 
who did not bleed (Table 2). The number and nature of risk factors for 
bleeding patients was similar in PGE2 and placebo groups. 
There was no great difference in gastric acidity between the PGE2 
and placebo groups, nor between patients with bleeding and those 
without bleeding (Table 3). There was also no statistical difference 
in gastric acid output (mmol/24 h) between these groups. 
Table 2. Risk factor distribution 
Category No. of No. of 
Patients Risk Factors 
Hemorrhage 
PGE
2 
patients 9 3.8 
Survived 1 3.0 
Died 8 3.9 
Placebo patients 13 3.5 
Survived 6 3.3 
Died 7 3.0 
Total 22 3.6 
Survived 7 3.3 
Died 15 3.5 
No hemorrhage 
PGE2 patients 20 2.9 
Placebo patients 15 2.5 
Total 35 2.7 
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Table 3. Duration of gastric pH~3.5 
Duration 
Category of treatment 
(days) 
PGE2 patients 
Hemorrhage 26 
No hemorrhage 102 
Total 128 
Placebo patients 
Hemorrhage 31 
No hemorrhage 75 
Total 106 
5.5 DISCUSSION 
Duration 
pH~3.5 
(days) 
19 
83 
102 
28 
58 
86 
Percentage 
73.1% 
81.4% 
79.7% 
90.3% 
77.3% 
81.1% 
Previous clinical trials with histamine-2-receptor antagonists have 
failed to demonstrate any clear-cut prevention of stress 
lesions. 8 • 10 • 11 • 15 Titration of the gastric juice with antacids to 
14 
achieve a constant pH appears to be effective, but is very 
difficult to accomplish in practice. 
Prostaglandins have a cytoprotective effect 18- 20 against injurious 
substances such as acetyl salicylic acid. 21 Although some 
prostaglandins (PGE
1
, PGE2 , PGA1 ) reduce gastric acid secretion when 
administered in high doses, cytoprotection is not dependent on changes 
22 in gastric acidity. The following changes probably play a role in 
cytoprotection: an increase in electric potential difference generated 
23 by an increased sodium transport from the lumen of the stomach ; 
increased chloride transport towards 24 the lumen 
bicarbonate and mucus secretion by the gastric mucosa 
increased 
25,26; and an 
27 increased mucosal blood flow. 
intracellular cyclic AMP. 23 
Prostaglandins also increase the 
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We found no clear-cut evidence that PGE2 prevented intestinal 
bleeding. Duodenal ulceration was 
small clinical trial by Johansson 
mg/day of PGE2 seemed to cure 
also not prevented, although a 
28 
and Kollberg found that 2.5 
duodenal ulcer. A larger study 
population would possibly show a statistically significant difference 
in the incidence of bleeding between PGE2 and placebo groups. However, 
because we were trying to find a highly effective means of preventing 
stress bleeding, and because statistical significance does not always 
mean clinical significance, extension of this study seems unjustified. 
In our study the PGE2 dose was below that which suppresses gastric 
acid secretion, but at a level reported to provide cytoprotection. 
Although we failed to demonstrate a beneficial effect with a PGE2 dose 
of 3 mg/day, a higher dose could be effective. However, this seems 
unlikely as Cohen 29 showed protective effects while using much lower 
dosages. Moreover giving more than 3 mg of PGE2 can cause undesirable 
side-effects. 
Our findings do not agree with theories that acids are the only 
cause of stress ulcers. On the other hand, the problem is very 
complicated. Reflux of alkaline duodenal fluids into the stomach 
could lower its acid content and favor the development of stress 
ulcers through detergent action of the bile salts. The damaged gastric 
. . ff . 30 mucosa also loses ac~d through back-d~ us~on. 
The spectrum of upper intestinal lesions should be considered when 
evaluating stress-induced bleeding. Sampling gastric fluid through an 
intraluminal tube and measuring its blood content with the 51Cr-method 
detects not only gastric bleeding sources but also esophageal and 
duodenal lesions, as evidenced by our findings. However, only gastric 
ulcers and erosions should be considered true stress lesions, i.e. due 
to physiologic stress. Duodenal ulcers have been related to 
psychologic stress, which is also present in ICU situations. 
Esophageal lesions are mainly due to mechanical factors, such as 
gastric tube irritation and recumbent posture. 
We found no correlation between peroxidase test results and the 
51
cr-method. However, in all cases of bleeding indicated by the 
51
cr-method a bleeding site was confirmed by endoscopy. This suggests 
58 
that bleeding documented only by guaiac or orthotolidine tests, as 
8,14,15,31 done in previous studies, is not reliable without 
endoscopic confirmation. Future studies on the prevention of stress 
bleeding should be based on the 51cr-method and, ideally, endoscopy. 
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Chapter 6. 
Orthotolidine test not to be used for detection 
of blood in gastric juice 
6.1 INTRODUCTION 
A peroxidase test for detecting occult blood in gastric aspirates 
has been used as a criterion for haemorrhage in several studies on 
stress-induced upper intestinal bleeding. Hastings et al (1), Priebe 
et al (2) and Zinner et al (3) used the guaiac test while Pingleton 
and Hadz:ima (4) based their study on the orthotolidine method. Both 
tests depend on the peroxidase activity of iron-containing haemoglobin 
derivates, which catalyse the oxidation of guaiac or orthotolidine in 
the presence of hydrogen peroxide. The guaiac test is intenqed for the 
investigation of faeces, the pH of which varies between 6 and 8. The 
orthotolidine test is usually employed to detect occult blood in 
faeces or urine. It is questionable whether such tests are sui table 
for the detection of blood in gastric aspirates which have a much 
lower pH. However conclusions regarding the prevention of stress 
ulcers have been based on the results of such colorimetric tests 
(1-4). 
During a study of prophylaxis of stress-bleeding in intensive care 
patients, we encountered marked discrepancies between 
orthotolidine test in gastric juice and those based on 
results of the 
51 . Cr-labellJ.ng 
of the patient's erythrocytes, which suggest that the orthotolidine 
method is not sui table for gastric juice analysis, and which cast 
doubt on the conclusions drawn in the studies cited. 
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6.2 METHODS 
Twenty-one patients admitted to a medical or surgical intensive 
care ward were investigated. The study was done within the scope of a 
prospective stress-bleeding prophylaxis trial~ which was approved by 
the Medical Ethics Committee of our hospital. The patients were 
randomized to receive prostaglandin E2 or placebo. Patients who were 
fed enterally were excluded from the study. No antacids or histamine-2 
antagonists were given. Ten milliliters of blood were taken, labelled 
51 
with 1.11 MBq Cr-chromate and readministered intravenously to the 
patient (5). Blood content in gastric juice was determined in 24-h 
collections in a large volume gamma counter (Armac, Brussels), using 
10 ml of the patient's blood taken on the same day as a standard. 
Gastric juice was obtained by a nasogastric tube and collected in 4-h 
portions which were kept refrigerated at 4°C until the 24-h collection 
period was completed. The colour of the gastric juice was noted and 
the pH measured. 
Mul tistix (R) (Ames, IN, USA) was used as the orthotolidine test. 
The reagent contains 9.0% wjw cumene hydroperoxide, 2,4% wjw 
orthotolidine, 22% wjw buffer and 66.6% nonreactive ingredients. The 
gastric juice was diluted 1:20 with water, as we had determined 
previously that a blood loss of about 10 ml/24 h would give a 3+ 
reaction at this dilution. Subsequently, a series of 23 samples was 
tested undiluted and in a 1:10 dilution with water. To investigate the 
effect of adjusting the pH of the gastric juice on the test result, 
the test was repeated in portions of gastric juice in which the pH had 
been brought to pH 7.0 with NaHC03 during dilution. The test strip was 
dipped into the gastric aspirate and read after 40 s. 
The following colour classification was used: yellow, negative; 
yellow-green, trace; green, +; blue-green, 2+; blue, 3+. 
6.3 RESULTS 
The results are shown in Tables I and II and in Fig. 1. 
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Table I. 
Twenty-four hours' gastric juice analysis of 11 patients 
Volume Colour pH Multistix 
(ml) 1:20 dil. 
903 green 1.7 trace 
1,154 green 2.6 trace 
634 green 1.7 + 
1,884 green 2.5 + 
979 green 1.8 + 
578 green 1.4 + 
992 gray 1.6 + 
1135 green 2.3 + 
1,539 yellow 2.4 + 
566 green 1.4 + 
924 green 1.4 + 
920 green 1.3 + 
988 green 4.1 2+ 
998 green 1.3 2+ 
734 green 1.3 2+ 
475 green 1.2 2+ 
425 green 1.5 2+ 
312 green 1.4 2+ 
617 green 1.4 2+ 
1,300 green 1.2 2+ 
287 green 1.4 2+ 
366 green 1.5 2+ 
480 green 1.4 2+ 
609 green 1.9 2+ 
417 green 1.5 2+ 
602 green 1.5 2+ 
479 brown 1.6 2+ 
703 brown 3.1 2+ 
505 brown 5.3 3+ 
710 green 3.5 3+ 
253 brown 1.7 3+ 
Blood ( 51Cr) 
(ml/1 gj a) 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
1 
2 
3 
3 
<1 
1 
3 
4 
4 
4 
5 
5 
5 
5 
5 
5 
7 
8 
16 
30 
12 
12 
22 
---------------------------------------------------------------------
a gj, Gastric juice. 
65 
Table II. 
Twenty-four hours' gastric juice analysis of 10 patients 
Volume 
(m1) 
617 
1,374 
2,487 
258 
623 
845 
1,197 
954 
1,427 
573 
405 
460 
629 
529 
500 
926 
972 
590 
909 
590 
657 
461 
468 
Colour 
yellow 
yellow 
green 
green 
yellow 
green 
green 
brown 
green 
b 
bs 
green 
bs 
bs 
green 
green 
green 
green 
green 
brown 
green 
green 
green 
brown 
a gj, Gastric juice. 
b bs, Bile-stained. 
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pH 
1.6 
1.5 
1.1 
2.0 
1.9 
1.4 
1.3 
1.2 
1.8 
7.3 
4.3 
7.1 
6.8 
1.7 
1.6 
1.8 
3.6 
1.4 
1.9 
1.5 
2.3 
6.9 
3.1 
Multistix 
51 Blood ( Cr) 
undil. 1:10 dil. 1:20 dil. (ml/1 gj a) 
trace 
trace 
trace 
+ 
+ 
+ 
+ 
+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
3+ 
3+ 
3+ 
3+ 
trace 
trace 
2+ 
+ 
trace 
+ 
2+ 
2+ 
+ 
+ 
3+ 
2+ 
+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
2+ 
3+ 
3+ 
trace 
trace 
+ 
+ 
trace 
trace 
trace 
2+ 
+ 
+ 
2+ 
+ 
+ 
+ 
2+ 
+ 
2+ 
2+ 
+ 
2+ 
2+ 
2+ 
2+ 
<1 
<1 
2 
<1 
<1 
<1 
2 
11 
<1 
<1 
<1 
<1 
1 
2 
2 
3 
5 
9 
18 
1 
2 
5 
149 
rul blOOd/ 1 <Jastrie JUice 
{51 cr m.::-trho=ct='----------------------------, 
• 
• 
• 
• • 
.. , .. 
--
.... 
+ ++ +++ 
Orthotolidine t.::-st r.::-sults 
Fig.l. Comparison of 24-h collections gastric juice. Concentration of 
51 blood as measured by Cr-method and colour classifications 
from orthotolidine tests after 1:20 dilution of the same 
gastric juice samples. 
The orthotolidine method did not correlate with blood loss per 24 h 
nor with the concentration of blood in the gastric juice, as measured 
by the 51cr-method. Lower colour scores were sometimes found in 
undiluted gastric juice than in the 1:10 and 1:20 dilutions. 
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20 
DORlGINAL pH 
16 
LSJ pH 7.0 
12 
8 
4 
+ + 
Fig.2. Total numbers of gastric juice samples with particular colour 
test results before and after neutralization. 
Adjusting the pH of the gastric juice to 7. 0 did not cause a 
significant change in the orthotolidine test results (Fig.2) and 
failed to improve the correlation with the 51cr-method. 
Under these test conditions we failed to find a constant 
quantitative relationship between blood content as measured by the 
51
cr-method and test strip readings. 
6.4 DISCUSSION 
The 51cr-method of determining gastrointestinal blood loss is 
generally regarded as the most reliable method available (6). The 
results we obtained using this method were not reproduced by the 
colorimetric method based on the peroxidase reaction. Fisher and Hunt 
(7) showed in 1976 that the effect of haemoglobin on the conversion of 
orthotolidine is decreased at a low pH. The manufacturers of Multistix 
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warn that a high specific gravity or a high protein concentration 
decrease the reactivity of the test. The presence of reducing 
substances can also lead to false negative results; oxidizing 
substances can give false positive results. Multistix is intended to 
detect occult blood in urine. Layne et al (8) have drawn attention to 
the effects of antacids, cimetidine and the gastric pH on the 
reaction. Adjusting the pH of the gastric juice did not improve the 
correlation with 51cr-method in this study. 
In light of our findings, the peroxidase method cannot be regarded 
as a reliable method for detecting blood loss from the upper 
gastrointestinal tract. This study also casts doubt on the validity of 
conclusions concerning the prevention of stress-bleeding which were 
based on the peroxidase reaction in gastric aspirates as a criterion 
of gastrointestinal haemorrhage. 
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Chapter 7. 
Determination of haemoglobin in gastric aspirates 
7.1 SUMMARY 
The haemoglobin content of gastric aspirates can be quantitated by 
conversion of non-fluorescent haem to fluorescent porphyrins by 
heating gastric aspirates with oxalic acid and ferrous sulphate. 
Recovery of haemoglobin added to gastric aspirates was 92 ± 9%, 
variation coefficient, n = 52, day to day variation was less than 8%. 
This method was used to calculate blood (haemoglobin) loss in 211 (24 
hours) gastric aspirates obtained from 58 intensive care patients. 
Gastric blood loss was also measured by the 51cr radiolabelled 
erythrocytes method in the same samples. There was a good linear 
correlation (r 0.942, p <o.OOl) between the two methods. The 
fluorimetric method of quantitating haem is therefore sui table for 
detecting and measuring blood loss in gastric contents. 
7.2 INTRODUCTION 
The determination of haem0globin in gastric aspirates has been used 
in several studies to detect upper gastrointestinal bleeding (1-4). In 
most studies a peroxidase assay, using guaiac or orthotolidine, has 
been used. Such leuko dye tests are qualitative rather than 
quantitative, and have been shown to be unreliable tests for occult 
blood in gastric juice (5). A reliable alternative is the quantitative 
measurement of 51cr radiolabelled erythrocytes. This method is however 
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costly, invasive and not sui table for routine use. Recently Schwartz 
et al (6. 7) described a method for measuring haemoglobin in faeces 
which is based on the removal of iron from haem by heating under 
reducing acid conditions to convert it to fluorescent porphyrin. This 
test, which is based on methods described for whole blood and tissues 
(8), has been shown to be quantitative and specific over a wide range 
of haemoglobin concentrations in faeces (6). We have applied a 
modification of their method to the determination of haemoglobin in 
gastric aspirates, and compared the results obtained by this method to 
51 1" f ' those obtained by Cr-label ~ng o the patient s erythrocytes. 
7.3 MATERIALS AND METHODS 
Gastric aspirates were obtained from a series of adult intensive 
care patients participating in a double-blind, placebo-controlled 
study of the effects of prostaglandin E2 on the occurrence of upper 
gastrointestinal haemorrhage in intensive care patients. Details of 
the patients and of the protocol have been described elsewhere (9). 
Briefly, either placebo or prostaglandin E2 was introduced into the 
stomach by a nasogastric tube at 4 hourly intervals, and gastric 
contents allowed to drain by gravity between administrations. Gastric 
contents were kept at 4°C until 24 hour collections could be pooled, 
after which the 24 hour collections were kept at -20°C. A total of 211 
samples obtained from 58 patients were available for both the 
51 Cr-labelled erythrocytes and the chemical analysis. This study was 
approved by the Medical Ethics Committee of the University Hospital of 
Rotterdam. 
7.3.1 51cr chromate labelling. 
Blood (10 ml) was withdrawn from the patient, the erythrocytes were 
51 labelled with 1.11 MBq of Cr chromate, and readministered to the 
patient (10). The radioactivity of the pooled collections of gastric 
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juice was measured in an Armac (R) large volume gamma counter (NV 
Packard Instruments Brussels, Belgium). Ten ml of blood was withdrawn 
daily and used as standard. The haemoglobin content of the blood was 
measured daily by the HiCN method in a Coulter S instrument (Hoek-Loos 
BV, Schiedam, The Netherlands). The results of the 51 . Cr-labell~ng 
studies, expressed in ml blood per 1 gastric aspirate, were co~verted 
to mmol Hb per l aspirate using the Hb concentration of peripheral 
blood on the morning of the collection day. 
7.3.2 Fluorimetric method of haemoglobin determination. 
This method is based on that described by Schwartz et al (6,7) in 
which haem is broken down to iron and porphyrins (mainly dicarboxylic 
porphyrins such as protoporphyrin) by heating with oxalic acid and 
FeS04 , but is modified in that the resulting porphyrin is extracted 
from the reaction mixture by isopropanol. 
7.3.3 Reagents. 
Crystalline haemoglobin was obtained from Sigma, St. Louis, Mo, 
USA. Haemoglobin stock standard was made by dissolving 20 mg of 
haemoglobin in 10 ml 9 g/1 NaCl, corresponding to 124 umo1/L 
haemoglobin. The following dilutions were made with 9 g/1 NaCl: 1:20, 
1:10, 1:5, 1:2.5 and these, together with undiluted stock standard 
were used as standards for the assay. 
7.3.3.1 Oxalic acid reagent. 
2.5 mol oxalic acid (315 g c2a 2o4 , 2H20), 
7H20, 50 mmol (8.4 g) uric acid, 50 mmo1 
90 mmo1 (25 g) Fe SO 4 . 
(9.1 g) mannitol in 
bidistilled water to 1 l, was made fresh each day and heated to 80°C 
on a thermostatted hotplate while being mixed constantly with a 
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magnetic stirrer, during 1 hour, before use. The reagent remains as a 
suspension, and was kept at 80°C while being stirred until use. A 
separate volme of reagent, kept at room temperature, was used for the 
blank determination of each sample. 
7.3.4 Procedure. 
Collections of gastric juice were mixed well before sampling. In 
·specimens where the contents did not form a homogenous suspension, a 
solution could be achieved by the addition of NaOH. For the assay, 50 
ul of gastric juice was mixed with 50 ul of 9 g/1 NaCl in a 
polypropylene test tube. To this mixture 2 ml of reagent (80°C) was 
added by means of a graduated 2 ml glass pipette and the tube placed 
in a waterbath at 100°C with a marble on top to prevent evaporation 
losses. After 30 min at 100°C the tubes were cooled under running tap 
water and 2 ml of isopropanol was added when cooled. The contents were 
then mixed on a vortex mixer followed by centrifugation at 1200 g for 
10 minutes. The supernatants were then tranferred to a Perkin Elmer 
spectrofluorimeter (type 2000) (Perkin-Elmer Nederland BV, Gouda, The 
Netherlands) with a red sensitive photomultiplier and the fluorescence 
read at 399 nm excitation and 598 nm emission wavelengths. 
Standards were run in a similar way by mixing 50 ul of each 
haemoglobin standard with 50 ul 0.01 mol/1 HCl. Recoveries were 
determined by adding 50 ul haemoglobin standard to 50 ul sample . 
A blank was prepared of each sample and standard. The order of 
addition of reagents to blanks was first the isopropanol (2 ml), 
followed by the oxalic acid reagent (2 ml at 20°C). This mixture was 
left at room temperature for 30 minutes. Centrifugation and subsequent 
measurements were carried out as described above. 
The fluorescence of the sample minus fluorescence of the sample 
blank was compared with the fluorescence curve of the standards minus 
standard blank. Recoveries were performed by adding 50 ul of the 1:5 
haemoglobin standard to 50 ul of sample. Reproducibility was checked 
by performing the test on two series of multiple assays on separate 
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days. All determinations were done in duplicate. Completeness of 
extraction of porphyrins was checked 
added protoporphyrin IX (obtained as 
by measuring the recovery of 
disodium salt from Pfal tz & 
Bauer, Flushing, NY, USA) in concentrations ranging from 11.4 to 114 
umol/1 in gastric aspirates from 3 patients. 
7.3.4.1 HPLC of porphyrins. 
The nature of the porphyrins, formed by heating gastric aspirates 
with the oxalic acid reagent and extracted from the mixture into 
isopropanol, was examined by 
liquid chromatography (11). 
7.4 RESULTS 
7.4.1 Recovery and reproducibility. 
reversed phase high performance 
The isopropanol extraction method was found to extract all added 
protoporphyrin (recovery 100,3 ± 5.4%). Mean recovery of haemoglobin 
added to gastric aspirates was 92% (variation coefficient 9%, n =52). 
Reproducibility was good, e.g. two samples gave 11.86 ± 0.95 (mean ± 
SD, n = 8) and 51.48 ± 3.39 (n = 6) umol/1 haemoglobin. 
7.4.2 Comparison with 51cr-labelled erythrocytes method. 
The results of the comparison of the fluorescent method and the 
radiolabelled erythrocytes method for the 211 gastric aspirate samples 
is shown in fig.l. A good correlation was found over a wide range of 
concentrations. 
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measured fluorimetrically or by Cr-labelled erythrocytes. 
The dotted line represents the line of identity 
(y = 1.03 x- 0.25; r = 0.942, p <o.OOl). 
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7.4.3 HPLC of fluorescent products. 
Chromatograms of the porphyrins formed from gastric aspirates and 
extracted by isopropanol are shown in fig.2. 
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Fig.2. HPLC chromatograms of the porphyrins formed by acid reduction 
of haemoglobin in a gastric aspirate (b), in comparison with 
the blank of the same gastric aspirate (a) (protoporphyrin is 
eluted at 14 min (peak 1), haematoporphyrin between 10 and 12 
mins (peak 2). 
Most porphyrins found under both situations are dicarboxylic 
porphyrins - mainly protoporphyrin. There was almost no detectable 
fluorescence in the blank determination of the specimen. 
The fluorescence emission spectra for treated haemoglobin, gastric 
aspirate and blank are shown in fig.3. 
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Fig.3. Fluorescence emission spectra of the isopropanol extract of th< 
blank of a gastric aspirate (a), a treated gastric aspirate (b 
and the treated haemoglobin standard (c) (excitation wavelengtl 
399 nm). 
7.5 DISCUSSION 
The fluorimetric method of determining haemoglobin in faeces ha1 
been reported to be quantitative and accurate over a wide range o· 
haemoglobin concentrations (6, 1), and this we could confirm. In thi1 
study, measuring haemoglobin in gastric aspirates, we simplified th~ 
method described by Schwartz et al (6) for faeces by reducing th~ 
extraction of porphyrins after the acid reduction to a single step 
Isopropanol extracts mainly the lipid soluble porphyrins such as th~ 
dicarboxylic porphyrins which are formed when iron is removed fro1 
haem. This single extraction step has proven reliable for measurinl 
haem (haemoglobin) in gastric aspirates, and preliminary studie: 
suggest that it is also applicable to faeces, and that even for faece1 
there is negligible interference by endogenous porphyrins (except il 
patients with protoporphyria) or by chlorophyll. 
This study shows a good correlation between this new quantitativt 
test of gastric blood loss and the accepted test which use: 
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radiolabelled erythrocytes. The differences in individual values 
between the two tests in this series could be due to problems in small 
scale sampling because of the inhomogeneity of gastric juice, and to 
the difficulties in measuring low levels of blood loss accurately with 
the radiolabelling technique due to the small amounts of 51cr in the 
samples. Blood in gastric aspirates is not distributed evenly, and it 
is sometimes difficult to obtain a homogenized mixture. Alkaline 
dilution. however, promotes solubilisation of proteins and haemoglobin 
and facilitates sampling. The good agreement found in this direct 
comparison of the two methods suggests that the technically simpler 
fluorimetric method can be used instead of the radiolabelling 
technique in clinical studies or clinical practice where detection and 
quanti tat ion of gastric blood loss is needed. It is sui table for 
subjects in whom radioisotope studies are contraindicated. 
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ChapterS. 
DNA in gastric aspirates 
8.1 INTRODUCTION 
Prostaglandins are thought to 'have a stimulating effect on the 
synthesis of desoxyribonucleic acid (DNA) in the stomach mucosa. In 
rats, acetylsalicylic acid inhibits DNA synthesis in the gastric 
mucosa. This inhibition and the subsequent ulcer formation could be 
prevented by administration of prostaglandins (1). Studies in guinea 
pigs (2) have shown that stress decreases DNA synthesis in gastric 
mucosa. 
Croft and Cotton (3) showed that DNA output in gastric aspirates is 
a measure of cell turnover in the gastric mucosa, and thus for 
exfoliation and cellular renewaL The normal gastric juice of humans 
contains up to 30 mg per day of DNA. A more exact determination of 
cell renewal than the DNA content, is the measurement of incorporation 
of titriated thymidine in mucosa. Kim et al (4) and Lipkin et al (5) 
found that in rats stress results in a decreased mitotic activity in 
the gastric mucosa. Stremple (6) performed clinical studies in 
patients with multiple or severe trauma. He found an increase in the 
DNA output in the gastric juice during the first days of the trauma. 
The time course of DNA output appeared to be related to the severity 
of the trauma. 
We tried to study whether: 
1. Prostaglandin E2 (PGE2 ) influences DNA output in gastric juice; and 
2. The DNA output could be related to the number of risk factors for 
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stress bleeding. 
8.2 METHODS 
As part of the clinical trial on stress bleeding prophylaxis using 
PGE2 versus placebo, described in chapter 5, gastric aspirates from 
all patients were kept -20°C. The DNA content was measured according 
the method of Croft and Lubran (7) which is designed to measure DNA in 
human gastric washings. This is a modified diphenylamine method, which 
leads to the spectophotometric determination of DNA. 
Gastric aspirates of day 1 were not examined as these were initial 
portions at the moment of starting the study, which did not allow 
calculation of output. Day 2 was the first complete 24 hour period. To 
allow statistical evaluation, only the results of patients which 
completed a minimum of 3 days in the trial, were used. This means that 
a number of patients who bled during the first days of the study were 
excluded from the calculations. The DNA output was calculated by 
multiplying the DNA concentration (ug/ml) by the 24 hour gastric 
aspirate volume. The DNA output is expressed in mg/day. 
Blood loss into gastric 
51
cr-labelling method (8). 
8.3 RESULTS 
aspirates was determined by the 
DNA outputs over 3 days are given in table 1 and table 2. A trend 
in the DNA output over these 3 days could not be demonstrated. The 
total 3 day DNA output is given in table 3 to examine possible effects 
of PGE2 on DNA output. For an improved comparison of PGE2 with 
placebo, the patients were stratified according to the number of risk 
factors. A statistically significant quantitated difference in DNA 
output between the PGE2 and the placebo group was not found. There was 
no relationship between the number of risk factors (a measure of the 
severity of the stress) and DNA output during 3 days. 
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Table 1. PGE2-group 
DNA output (mg/day) 
Patient's No. No. of RF Day 2 Day 3 
1* 5 17,4 9,7 
2 5 53,5 43,1 
3* 4 5,6 1,4 
4 4 26,0 7,7 
5*T 3 19,5 26,5 
6 3 13,4 22,0 
7 T 3 12,0· 3,8 
8 3 6,5 18,2 
9 3 99,2 84,9 
10 3 16,7 9,6 
11 3 6,C 10,5 
12 3 7,9 3,9 
13 2 7,9 32,1 
14 2 9,3 5,1 
15 2 2,2 8,4 
16 2 10,2 2,5 
17 2 20,7 47,0 
* Patient with bleeding ( ~ 15 ml/day) 
RF risk factors 
T trauma patient. 
(mg/3 days) 
Day 4 Day 2+3+4 
7,3 34,4 
24,7 121,3 
1,3 8,3 
9,6 43,3 
11,4 57,4 
11,6 47,0 
12,2 28,0 
22,4 47,1 
84,3 268,4 
17,2 43,5 
7,2 23,7 
3,8 20,6 
39,9 89,9 
1,4 15,8 
2,3 12,9 
2,2 14,9 
25,7 93,4 
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Table 2. Placebo group. 
DNA output (mg/day) (mg/3 days) 
Patient's No. No. of RF Day 2 Day 3 Day 4 Day 2+3+4 
1* 4 5,1 2,4 5,6 13,1 
2* 4 22,1 90,1 28,6 140,8 
3 4 1,2 14,1 8,6 23,9 
4 3 28,6 22,0 12,5 63,1 
5 3 2,2 9,4 4,5 16,1 
6 3 20,3 27,3 5,4 53,0 
7* 2 11,7 36,9 8,3 56,9 
8 2 2,8 2,8 0,9 6,5 
9 2 9,6 6,7 11,7 28,0 
10 2 11,8 11,6 18,8 42,2 
11 2 6,6 1,1 4,0 11,7 
12 2 6,0 4,4 5,7 16,1 
13 2 4,4 4,5 4,0 12,9 
----------------------------------------------------------------------
* Patient with bleeding ( :;J>15 m1/day) 
RF risk factors. 
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Table 3. Total DNA output in days 2 + 3 + 4 (mg/3 days) as mean value 
per patient. 
----------------------------------------------------------------------
No. of RF 
5 
4 
3 
2 
RF = risk factors. 
77,9 (2) 
25,8 (2) 
67,0 (8) 
45,4 (5) 
Numbers of patients in parentheses. 
8.4 DISCUSSION 
placebo 
(0) 
59,3 (3) 
44,1 (3) 
24,9 (7) 
We were unable to confirm in this study the findings of Stremple 
(6), who found an increase in DNA output during the first days 
following trauma. This could be due to the fact that a few trauma 
patients were included in our study, and large number of patients with 
other serious conditions. The two trauma patients we examined, 
however, also did not show a change in DNA concentration similar to 
that observed by Stremple. Patients who bled, did not have obviously 
different values to patients who did not bleed, nor was there a change 
in DNA content during the course of 3 days in the patients who had 
bled. We did not find an obvious effect of PGE2 on DNA output. The 
number of risk factors at the start of the study also did not 
correlate with DNA output. In healthy volunteers Hurst et al (9) was 
also unable to find an increase in DNA output in gastric juice 
following administration of PGE2 . The studies described above do not 
allow the conclusion to be drawn that PGE2 in stress has no effect on 
DNA synthesis, as a decreased exfoliation can mask an increased DNA 
synthesis. A study of a larger number of patients could possibly allow 
more definite conclusions to be drawn. 
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Chapter 9. 
Treatment and prevention of stress ulcer and stress 
bleeding 
9.1 INTRODUCTION 
The incidence of bleeding from stress ulcers seems to have 
decreased in recent years (1). This decrease has been ascribed to 
improved management of risk factors, especially sepsis and shock. 
Rapid recognition and correction of these predisposing conditions for 
stress ulcer and stress bleeding, are the mainstay of stress ulcer and 
stress bleeding prophylaxis and treatment. A significant bleeding, -
i.e. manifest hemorrhage requiring blood transfusions - from stress 
ulcer is associated with a high mortality of more than 30% (2,3). 
9. 2 TREATMENT 
9.2.1. General measures. 
Bleeding should prompt the attending doctor to look for and to 
treat rigorously underlying serious conditions. In suspected sepsis, 
all efforts should be taken to localize the source, drainage should be 
performed if possible, and appropriate antibiotic therapy should be 
given. Shock must be treated vigorously. Coagulation disorders should 
also be corrected (2,3,4). A large-bore tube should be inserted, in 
order to allow gastric decompression and to reduce vomiting and 
aspiration. It will provide also an impression about the rate of 
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bleeding. Some authors have reported a beneficial effect of gastric 
lavage (2,3,5). Iced saline lavage has been reported to stop 80% of 
bleeding episodes (2,6). There is evidence, however, that low 
temperature may retard clotting (2,4,5). Washing with fluid at room or 
body temperature is probably better, and, at least, serves to clean 
the stomach for subsequent gastroscopy. 
Intragastrically administered norepinephrine has been used in the 
treatment of gastric bleeding. There is little evidence that cold 
saline lavage or lavage with saline plus norepinephrine are better 
than lavage with room temperature saline for stopping bleeding (5,8). 
9.2.2 Antacids. 
Recent reviewers recommend the administration of antacids via a 
gastric tube, and to titrate gastric pH to ~7 (4,9,10). In vitro 
studies have demonstrated that acid has anticoagulant properties (11). 
Pepsin promotes platelet disaggregation (11), and is inactivated at 
high gastric pH. In the majority of patients, bleeding ceases with 
this type of management (4,9). Titration of gastric pH is, however, a 
tedious method for the nursing staff. 
9.2.3 Histamine-2-antagonists. 
The effectiveness of histamine-2-antagonists (H2-antagonists), such 
as cimetidine and ranitidine, in stopping upper gastrointestinal 
bleeding from different sources has not been proven (12,13). The 
available data indicate that in bleeding from peptic ulceration, 
rebleeding may be prevented by H2 -antagonists (14 ,15); combination 
with antacids seems to improve rebleeding prophylaxis (16). To date, 
there are no prospective randomized endoscopically controlled studies 
that indicate that cimetidine is effective in controlling established 
bleeding from acute gastric mucosal ulceration (10). Rebleeding from 
stress ulcers can possibly be prevented by H2-antagonists plus 
antacids (17). 
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9.2.4 Tranexamic acid. 
Tranexamic acid, an antifibrinolytic drug, was not associated with 
any decrease in the rate of rebleeding or the need for operation, in 
bleeding from different upper gastrointestinal sources in a recent 
study (18). However, stress ulcers were not included. 
9.2.5 Somatostatin. 
Somatostatin is a hormone that inhibits stimulated gastric acid and 
pepsin secretion and reduces splanchnic blood flow. It has been 
reported to be more 
from peptic ulcers 
effective than cimetidine in stopping bleeding 
(19,20). These studies are small and poorly 
controlled, and do not deal with stress bleeding. In a recent study by 
Somerville et al (21), 630 patients with bleeding from different upper 
gastrointestinal lesions were randomly allocated to treatment with 
somatostatin and placebo. No clear-cut benefit from somatostatin was 
found. 
9.2.6 Prostaglandins. 
There are some reports of treating bleeding from stress ulceration 
succesfully with prostaglandins (22, 23). No clinical trials have been 
reported using prostaglandins for this specific purpose. 
9.2.7 Therapeutic angiography. 
If bleeding 
Athanasoulis et 
persists, 
al (24) 
angiography 
reported on 
should be considered. 
their experience with the 
selective intra-arterial infusion of vasopressin in patients who were 
bleeding from acute gastromucosal lesions. Hemorrhage was controlled 
in 84%. The left gastric artery should be canulated and there is need 
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for an indwelling catheter. Though vasopressin is metabolized by the 
liver, there is a risk of cardiac side effects. Intravenously 
administered vasopressin is of no use in upper gastrointestinal tract 
bleeding, except in hemorrhage from varices (25). 
In a recent study, Lieberman et al (26), using gelfoam and/or coil 
springs had attained control of bleeding in 6 out of 11 patients with 
stress ulcers, i.e. a success rate of 55% in this small group of 
patients. 
For this hemostatic technique to be effective, one major artery 
should be supplying the area of bleeding, but in the stomach this is 
rarely the case as there is an extensive submucosal plexus. Moreover, 
stress ulcers are often multiple. An infrequent but serious 
complication of arterial embolization is gastric infarction. It seems 
reasonable to attempt therapeutic angiography before operation is 
considered, initially giving intra-arterial infusion of vasopressin. 
Failures of vasopressin can be followed by transcatheter embolization 
(27). 
9.2.8 Endoscopic therapy. 
Endoscopic hemostatic techniques e.g. electrocoagulation and laser 
coagulation are currently in the investigational stages. This mode of 
therapy probably offers the best non-surgical means for controlling 
upper intestinal hemorrhage. Efficacy and safety should be more 
completely evaluated, before routine clinical use can be advocated. 
Stress bleeding poses a special problem as stress ulcers are mostly 
multiple. 
9.2.9 Surgical therapy. 
In most patients bleeding stops after saline lavage, antacid or 
others of the aforementioned measures. Surgical intervention should be 
considered if bleeding persists, as evidenced by the need of multiple 
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transfusions of blood. Surgery should be viewed as a last resort. In 
these seriously ill patients an addi tiona! surgical procedure for 
control of bleeding has a mortality of 30 to 40 percent (3,10). A 
variety of operations has been proposed. The superiority of one from 
another has not been demonstrated (3). In general, the less extensive 
procedures are associated with lower mortality ra~es, bu~ high 
incidences of rebleeding (3). Truncal vagotomy and pyloroplasty with 
oversewing of lesions, is probably the best initial operation (3,4). 
Rebleeding occurs in 10 to 40 percent of cases and should first be 
treated medically (3). If conservative treatment of rebleeding is not 
successful, near total gastrectomy should be performed (3,4). Gastric 
devascularization is a new alternative approach, advocated by Ri-
chardson and Aust (28). This operation was reported to have low rates 
of rebleeding and gastric necrosis was not seen. Mortality, however, 
remained high, so in this respect gastric devascularization offers no 
advantage over the other operations. 
9.3 PREVENTION 
Significant hemorrhage from stress ulcer is associated with a high 
mortality and therapeutic results are disappointing. Therefore 
prophylaxis of stress ulcer and bleeding are rational. 
It should be emphasized that the best prophylaxis is rapid treatment 
of underlying serious conditions (risk factors), like sepsis and 
shock, and giving effective renal and respiratory support (31). 
The aim of stress ulcer prophylaxis is to maintain the gastric 
mucosal integrety, which involves several aspects: mucosal 
permeability, secretion, mucosal blood flow, acid-base balance, 
pepsin, and prostaglandins (29). A decreased cellular proliferation of 
the gastric mucosa has been demonstrated during stress (30). Attempts 
to influence these facets of gastric mucosal integrety in conditions 
predisposing to stress ulcers have been made in the laboratory and in 
patients and will be discussed below. 
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9.3.1 Vitamin A. 
Vitamin A has been used for stress bleeding prophyla.xis as a 
deficiency of this vitamin was suggested in animal experiments. Some 
data show a possible effect of vitamin A in preventing stress ulcer in 
rats, but results in humans are anecdotal and inconclusive (31). 
9.3.2 Carbenoxolone. 
Carbenoxolone, which stimulates the synthesis of gastric mucus and 
increases the life span of gastric mucosal epithelial cells, was found 
to reduce the incidence of stress ulcer in the rat model (31). Though 
carbenoxolone has been used for duodenal ulcer in man, no clinical use 
in the prophylaxis of stress ulcer has been reported (31). 
9.3.3 Gastrin. 
Gastrin is a powerful stimulator of gastric acid secretion. In 
rats, pentagastrin protects against stress ulceration (32). This 
protective effect is shared by histamine and is probably mediated by 
stimulation of cells + to secrete H , thus increasing intramural pH, 
which enhances the gastric mucosal barrier (29,33). Mucus synthesis is 
increased by gastrin probably via increased acid output (34). Another 
biological effect of gastrin is stimulation of growth of gastric 
mucosa (35), which seems very important in stress conditions. 
9.3.4 Secretin. 
A double-blind trial by Spilker et al (36) using endoscopic 
criteria, gave evidence of effective stress ulcer prophylaxis by 
secretin. They ascribed this effect to reduced gastric acid and pepsin 
secretion together with a decreased serum gastrin level. The 
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explanation has a weak theoretical base, as gastrin may on the 
contrary prevent stress ulcer; moreover, secretin reduces gastric 
blood flow, which predisposes to stress ulcer formation. 
Nevertheless, their findings are of interest, as they performed 
endoscopies instead of using unreliable tests for detecting occult 
blood loss. Further studies are necessary before firm conclusions as 
to the value of secretin in stress ulcer can be drawn. 
9.3.5 Cholestyramine. 
Reflux of duodenal contents into the stomach plays an important 
role in stress ulcer pathogenesis (1). Bile acids and lysolecithin 
cause gastric-mucosal injury (37). Cholestyramine is a 
bile-acid-binding agent, which was used by Schumpelick and Grossner 
(38) for stress ulcer prophylaxis in a clinical trial which included 
68 subjects. They found only gastric erosions in one patient in the 
cholestyramine group (8 patients), and gastric stress ulcers in 2 
patients in the antacid group (24 patients), the latter being used as 
a control group. No lesions were found using cholestyramine plus 
antacids (36 patients). 
9.3.6 Vasodilatation. 
Selective vasodilatation of gastric vessels with isoproterenol 
during hemorrhagic shock protects against acute gastric mucosal 
lesions in dogs (39). This seems to be too complicated for clinical 
application. 
9.3.7 Bicarbonate. 
Disturbances of acid-base balance are important pathogenetic 
factors in stress ulcer. Active acid-secreting gastric mucosa has a 
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protective effect against stress ulcer (29,33). Administration of 
bicarbonate on the gastric serosa or intravenously prevents stress 
ulcer in animals (29,31)' and a high arterial bicarbonate 
concentration possibly reduces the risk of stress bleeding in man 
(40), but no clinical trials using parenteral administration of 
bicarbonate in the prophylaxis of stress bleeding have been done. 
9.3.8 Antacids. 
Gastric acid production is generally not increased in stress ulcer 
disease, and gastric acid is not the most important factor in its 
genesis. Nevertheless it has a permissive role in stress ulcer 
formation (41,43), as gastric mucosal injury is aggravated by the 
influx of acid. 
The effectiveness of antacid in the prevention of bleeding was 
investigated by Hastings et al (43) in a placebo-controlled trial 
involving 100 critically ill patients. Hourly titration was used to 
maintain the pH of gastric contents above 3.5. The reported incidence 
of bleeding was 25% in the placebo group and 4% in the antacid group. 
Bleeding criteria were based on frank blood in gastric aspirates and 
on guaiac tests for occult blood. All patients of the placebo group 
who were considered to have a bleed (12 out of 49) had "chemical 
bleeding", i.e. based on guaiac. Only one patient was found to have 
clinical bleeding (frank blood in gastric aspirate) and this patient 
was treated with antacids. Two out of 51 patients in the antacid group 
were assumed to have bled: the one with clinical bleeding and another 
patient with "chemical bleeding". As is described in chapter 6 of this 
thesis, peroxidase tests are not applicable to detecting occult blood 
in gastric juice, so "chemical bleeding" is not a good criterion. 
Zinner et al (44), using also guaiac tests, had similar results in 
treating with antacids (5% bleeds) as compared with placebo (20% 
bleeds). In this study, gastric pH was kept above 4.0, and 
concomitantly one group of patients was treated with cimetidine (14% 
bleeds). Each group consisted of 100 patients. 
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Khan et al (45) reviewed the case records of intubated patients 
with respiratory failure. In 420 patients massive upper 
gastrointestinal hemorrhage occurred in 40 of 420 patients (9.5%). In 
a prospective study hourly antacid gastric neutralization was started, 
maintaining gastric pH over 5; three of 210 patients treated in this 
way developed bleeding (1.4%). In 110 patients cimetidine 1800 mg 
daily was given; 3 of them had bleeding (2.7%). These patients had 
only one risk factor (respiratory failure), so this study has 
significance for a special group of intensive care patients. 
Nevertheless, their findings are important as only clinical bleeding 
was used as a criterion. 
In a recent study (46) 65 critically ill patients were given 
prophylactic antacid treatment to maintain gastric pH of at least 5. 
Sixty-one patients received no prophylaxis. Microscopic bleeding was 
diagnosed with tests based on the peroxidase reaction. All patients in 
both groups developed microscopic bleeding. Moderate visible bleeding 
was seen in 7 patients of the antacid group (10.8%) as compared to 8 
patients in the control group (13.1%). This difference was not 
significant. One patient in the control group developed severe 
bleeding due to acute erosive gastritis. The authors conclude that 
antacids are not required to prevent stress bleeding. 
The rate of complications using antacids was 25% in the study of 
Hastings et al (43). Diarrhea is frequently seen. Metabolic alkalosis 
can occur. Aspiration pneumonia and hypermagnesemia are dangerous side 
effects, as is hypophosphatemia. Hypermagnesemia should be looked for 
in cases of renal failure. Recently, airway colonization and 
predisposition to pneumonia have been reported in seriously ill 
patients treated with antacids or cimetidine (47). 
9.3.9 Histamine-2-antagonists. 
Intraluminal gastric pH can be increased by histamine-2-antagonists 
(H2-antagonists) in an easier fashion than with antacids. 
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Administration is less time-consuming and the complication rate is 
much lower. 
Priebe et al (33) compared cimetidine and antacid in a stress 
bleeding prophylaxis trial in 75 patients. Gastric pH was measured 
hourly and titrated above 3. 5 in the antacid group, and cimetidine 
dosage was adjusted up to 2400 mg daily if pH was below 3. 5 in the 
cimetidine group. Seven of 38 in the cimetidine group developed 
bleeding (18%); 2 had clinical bleeding and 5 had "chemical bleeding". 
None of the 37 antacid treated patients had hemorrhage. The authors 
conclude that cimetidine does not adequately protect seriously ill 
patients from acute upper-gastrointestinal tract bleeding. The failure 
of cimetidine is ascribed to the impairment of the secretory state of 
the gastric mucosa, decrease of intracellular buffering capacity, and 
inadequate reduction of intraluminal acidity. Seven out of eight 
patients who required 400 mg of cimetidine every four hours had 
gastric pH values below 3.5 on one or more occasions even at that 
dosage. 
Zinner et al (44) found in 14% incidence of bleeding in 
cimetidine-treated patients as already mentioned above. In 34% of the 
patients treated with cimetidine, the gastric pH was not maintained 
above 4.0 (as was the aim in the design of this study) for longer than 
eight hours. 
Van den Berg and van Blankenstein (48) saw more patients with 
bleeding in a cimetidine-treated group of patients on assisted 
ventilation with multiple risk factors (5 out of 10), than in a 
placebo-treated group (one of 14). Bleeding was evaluated by the 
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cr-method. In a study by Luk et al (49) bleeding rate was also 
higher in the cimetidine-treated group than in the placebo-treated 
R group. Bleeding was defined on clinical grounds and Hemoccult tests. 
Cimetidine often elevates intragastric pH insufficiently, especially 
in severely stressed patients, even at high dosages. Martin et al (50) 
treated 39 critically ill patients with cimetidine, and in 11 of them 
(28%) pH could not be brought above 4.0. This failure of cimetidine 
(or antacids) to maintain gastric pH above 4.0 was found to be a sign 
of sepsis (51). 
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Stothert ct al (52) found cimetidine at a 1200 mg daily dosage to give 
pH above 4 in only 47% of critically ill patients, while maximal 
dosage (2400 mg) gave pH above 4 in 74% of patients. 
Side-effects of cimetidine are relatively rare. Fever, bone marrow 
suppression, and renal function impairment are sometimes seen. Mental 
confusion is seen more often, especially in the elderly. In 17% of 
critically ill patients mental symptoms were reported to be a 
consequence of cimetidine (53). Cimetidine has an inhibitory effect on 
hepatic drug metabolism. Interactions with other drugs has also been 
reported, including changes in absorption from the gut. 
In contrast to the disappointing results of cimetidine in the 
prevention of stress bleeding mentioned above, there have been 
non-randomized studies that indicate effectiveness, such as those of 
Jones et al (54) and MacDougall et al (55). Jones et al studied 
patients following renal transplantation. They found no bleeding in 3 
cimetidine-treated patients, whereas six of 33 patients (18%) who did 
not receive cimetidine developed hemorrhage. Bleeding was diagnosed on 
clinical grounds, and some of the patients underwent endoscopy. The 
lesions could not be called true stress ulcers, as many esophageal and 
duodenal lesions were seen in the untreated group. MacDougall et al 
compared antacids and cimetidine as prophylaxis for stress bleeding in 
patients with fulminant hepatic failure. Cimetidine appeared to have a 
better prophylactic effect against stress bleeding than antacids or no 
treatment. Antacids were given at four hour intervals. Prophylaxis 
failure was defined as the aspiration of fresh blood. Bleeding rates 
were 4%, 23% and 54% respectively. Gastric pH' was not consistently 
controlled in this study. 
Recently, an endoscopic study comparing cimetidine with placebo in 
patients in an intensive care unit has been reported (56). Though 
relatively small groups of patients were investigated, the results of 
the endoscopic findings are very suggestive of a beneficial effect of 
cimetidine in prophylaxis of stress ulcer and stress bleeding. 
Prevention of acute gastrointestinal complications after severe 
head injury was studied by Halloran et al (57). Five of 26 
cimetidine-treated patients (19%) and 18 of 24 placebo-treated 
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patients (75%) had hemorrhages, which were based on clinical findings 
and guaiac tests. They did not observe a difference in the incidence 
of mucosal lesions between the groups as far as endoscopies were 
performed. 
Prevention of gastroduodenal lesions following thermal injury has 
been reported by McElwee and others (58), in which the efficacy of 
cimetidine (13 patients) was compared to that of antacids (14 
patients). Duodenal disease was nearly eliminated and severity of 
gastric disease was markedly reduced when compared to that of 
untreated historical controls, in both treatment groups. Not all 
patients underwent endoscopy. 
The role of ranitidine, a new H2-antagonist, in the prophylaxis of 
true stress ulcers seems as controversial as that of cimetidine (13). 
9.3.10 Histamine-2-antagonist plus antacid. 
The use of cimetidine as the sole prophylactic agent remains 
controversial, although cimetidine may be effective in selected groups 
of patients with head injury (prevention of Cushing's ulcer) or 
thermal injury (prevention of Curling's ulcer), or severe liver 
disease (31). No well-done study has evaluated the relative efficacy 
of titrated-dose antacid versus the combination of cimetidine and 
antacid (59). The addition of cimetidine in patients on high-dose 
antacid and experiencing acid-base disturbances secondary to copious 
gastric secretions may be useful (59). On the other hand, if high 
dosages of antacids are not sufficient in maintaining pH above a 
certain value, the addition of cimetidine is not likely to raise 
intragastric pH, as was shown by Martin et al (50,51) and Stothert et 
al (52) in severely stressed patients. 
9.3.11 Sucralfate. 
Sucralfate is a complex of sulfated sucrose and aluminium 
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hydroxide, that is only minimally absorbed from the gastric tract. It 
produces an adherent complex with proteinaceous exsudate of ulcers. In 
vitro, a sucralfate-albumin film is a barrier to the diffusion of 
hydrogen ion. Sucralfate binds bile salts and inhibits pepsin. 
Sucralfate was found to be as effective as antacid in the 
prevention of stress bleeding in a study of Borrero et al (60). 
Antacids were titrated hourly to maintain gastric pH above 3.5. 
R Gastroccult paper tests were used for detecting occult blood. There 
was no gross bleeding in any of the patients. Three of the 48 
sucralfate-treated patients and 2 of the 52 antacid-treated patients 
had positive Gastroccul tR tests, i.e. 6% and 4% respectively. Its 
advantage over antacids is a reduction in nursing time by simpler 
administration and testing gastric pH seems unnecessary. Only 
"chemical bleedings" were seen in this trial. Endoscoppy was performed 
in only two patients who bled and minor degrees of stress ulceration 
were seen. To which treatment group these two patients belonged was 
not mentioned. 
Recently (61) cytoprotective properties mediated by stimulation of 
endogenous prostaglandins have been ascribed to sucralfate. 
9.3.12 Pirenzepine. 
Pirenzepine is a selective anticholinergic agent with affinity for 
specific muscarinic receptor sites. It inhibits in this way gastric 
secretion. Gastric mucosal microcirculation is maintained at an 
heightened level in the restraint ulcer model in rats (62). 
Pirenzepine probably has a place in prophyla..xis of Cushing's ulcer 
(63) and the incidence of stress lesions and bleeding was reduced in a 
small group of intensive care patients given pirenzepine (64). Stress 
ulcer and stress bleeding prophylaxis with pirenzepine in critically 
ill patients needs further investigation. Cytoprotective effects have 
been ascribed to pirenzepine (65). This form of cytoprotection is 
probably not mediated by prostaglandins. 
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9.3.13 Pirenzepine plus ranitidine. 
In a recent study (66) critically ill patients received either 
pirenzepine or ranitidine. Intragastric pH could be maintained above 4 
in only 6% and 22%, even at maximum dosages of pirenzepine (90 mg/day) 
and ranitidine (600 mg/day), respectively. Those patients in whom pH 
could not be maintained above 4, subsequently received pirenzepine 
plus ranitidine. In 11 of 15 patients (73%) pH correction could be 
achieved in this way. No clinical bleeding was seen. This study shows 
poor effects of pirenzepine as well as of ranitidine. Combination 
therapy provided better, though suboptimal, effects on intragastric 
pH. 
9.3.14 Prostaglandins. 
Prostaglandins are theoretically attractive for stress ulcer and 
stress bleeding prophylaxis because of their cytoprotective effects. 
Our trial could not show a clear-cut prophylactic effect using dosages 
at which cytoprotection is gained, without an effect on gastric acid 
secretion (see chapter 5 of this thesis). 
Recently Skillman et al (67) compared the prophylactic effect of 
lS(R)-15-methyl PGE2 with that of antacids, using Hemoccult as a slide 
test for occult blood in gastric aspirates. Three of 22 patients in 
the antacid group bled (14%) and 12 of 24 patients in the 
prostaglandin group bled (50%). As far as from this report can be 
gathered, only "chemical bleedings" were diagnosed. Endoscopies are 
not mentioned. Gastric pH was mostly above 3.0 in the 
prostaglandin-treated patients with hemorrhage, whereas in the 
antacid-treated patients with bleeding pH was between 7 and 8 in two 
patients and between 4 and 6 in a third patient. The authors suggest 
prostaglandin-analogues that do not require conversion from an 
inactive to an active form by acid may possibly give better results, 
as lS(R)-15-methyl PGE2 is epimerized in acid medium (pH below 3.0) to 
15(8)-15-methyl PGE2 , which has antisecretory properties. 
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To day, despite numerous reports 
animals, there are probably very 
of cytoprotective treatment in 
few clinical applications for 
prostaglandins in the prevention of stress ulcer. 
9.3.15 Nutrition. 
Parenteral nutrition, especially hyperalimentation, was found to 
augment gastric mucosal regeneration after surgery, allowing for more 
physiological secretory patterns and the maintenance of the protective 
gastric mucosal mechanisms (68), as evidenced by reduced exfoliation 
of cells and reduced incidence of bleeding. 
Preliminary data indicate enteral nutrition is important in the 
prophylaxis of stress bleeding (69) and may be better than antacids or 
cimetidine. 
Commercial milk preparations contain substantial amounts of 
prostaglandins and milk has been shown to be effective in the 
prevention of stress-induced gastric ulceration in the rat (70) . 
. Therefore, milk may be prefered when enteral nutrition will be 
administered. 
9.4 CONCLUSIONS 
The use of antacids, cimetidine and many other drugs in critically 
ill patients to prevent stress bleeding has no solid scientific 
foundation, as most studies on this subject used peroxidase tests 
(33,43,44,60,67), which are not reliable for detecting blood in 
gastric juice. 
If only clinically manifest bleedings are taken into account, 
published studies cannot be used to recommend antacids or cimetidine. 
Hastings et al (43) studying 100 patients found only one with 
hemorrhage which could be diagnosed on clinical grounds. This patient 
was in the antacid group. Fiddian-Green et al (40) saw massive 
bleeding in seven out of 103 patients in an intensive care unit. These 
seven patients were receiving antacids. Pinilla et al (46) did not see 
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a significant difference in the number of patients with visible 
bleeding comparing antacids with no specific prophylaxis. Cimetidine 
seemed to prevent bleeding in renal transplant patients in a clinical 
trial by Jones et al (54), but these patients were often found to have 
esophageal and duodenal lesions. In hepatic failure cimetidine seems 
to be better than antacids or no treatment, but in the study of 
MacDougall et al (55) there was no good control of gastric pH with 
antacids. The studies of Jones et al (54) and MacDougall et al (55) 
were non-randomized trials. Priebe et al (33) found clinical bleeding 
in the cimetidine group and not in the antacid group. 
On the basis of endoscopic criteria four studies merit special 
notice. First, Spilker et al (36) found evidence of stress ulcer 
prophylaxis in secretin-treated patients. The use of this hormone in 
intensive care patients needs further investigation. In another study 
(38) cholestyramine gave better protection against stress lesions than 
antacids, as was shown by endoscopy. No stress lesions were seen in 
patients treated with both cholestyramine and antacids. However, this 
treatment has not gained clinical application. Peura and Johnson (56) 
found beneficial effects of cimetidine regarding gastroduodenal 
mucosal lesions and bleeding severity in small groups of patients. 
Mattes et al (64) saw a reduction in the incidence of stress lesions 
and stress bleeding in pirenzepine-treated intensive care patients, 
which is a promising feature. Expented clinical trials are indicated 
as pirenzepine has a rational for use in stress conditions, as it 
probably preserves gastric microcirculation. 
51 Cr-labeling of erythrocytes enables reliable measurement of blood 
in gastric juice. Van den Berg and van Blankenstein (48) used this 
quantitative determination as a criterion of hemorrhage in their 
stress bleeding prophylaxis study. They found more cases of bleeding 
in the cimetidine group than in the placebo group. Chapter 5 of this 
thesis describes a trial with PGE2 , and no clear-cut effect on the 
prevention of stress bleeding could be shown, using the 51cr-method as 
a criterion of bleeding. 
In summary, we do not know which pharmacologic agent should be 
given in the prevention of stress ulcers and stress bleeding. 
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Reactivation of a chronic peptic ulcer can be prevented by antacids or 
H2-antagonists, and either of these should probably be given to 
patients with a history of peptic ulcer admitted to the intensive 
care. Curling's ulcer and Cushing's ulcer also can be prevented by 
antacids or H2 -antagonists. Prophylaxis of stress ulcers and stress 
bleeding consists of vigorous treatment of risk factors, giving 
optimal parenteral nutrition, and starting enteral feeding as soon as 
gastric decompression is no longer needed. 
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Chapter 10. 
Discussion and conclusion 
The stress ulcer syndrome is described in this thesis. This 
syndrome is seen in patients admitted to intensive care departments or 
being treated in field hospitals, in disaster areas, or battle fields. 
Acute mucosal lesions associated with burns (Curling's ulcers) and 
central nervous system disorders (Cushing's ulcers) appear to have a 
different pathophysiology and a different pathology to the real stress 
ulcers. 
Peptic ulcers and gastric lesions following use of non-steroidal 
anti-inflammatory agents also differ from stress ulcers. 
In chapter 2 the pathology of the stress ulcer is described. The 
true stress ulcer is usually found in the proximal part of the 
stomach, although it may rarely be seen in the distal part of the 
stomach or in the small or large bowel. Erosions are also included in 
the term stress ulcer. Histologically these are superficial defects 
which seldom reach the muscularis propria. 
The literature on the pathophysiology of stress ulcers is reviewed 
in chapter 3. Until recently, the mucous layer of the gastric mucosa 
has been considered to be of major importance. The discovery that the 
stomach has the capacity to produce bicarbonate, lead to the concept 
of a mucous-bicarbonate barrier with a demonstrable pH gradient over 
the mucous layer. As prostaglandins increase both bicarbonate 
secretion and mucus production, it is probable that prostaglandins 
play an important role in the maintainance of the gastric mucosal 
barrier. 
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Many authors point out the importance of gastric acid for the 
development of stress ulcers. Gastric acid appears, however, to act 
more in a permissive than causal fashion. The central feature in the 
development of stress ulcers is systemic hypotension, which leads to 
mucosal ischemia. Ischemia in turn gives rise to decreased energy 
production within the cell and subsequently cell necrosis. Studies 
described by Menguy support this theory of the development of stress 
ulcers, and provide an explanation for the sparing of the gastric 
antrum. 
Apart from hypotension or shock, additional risk factors are 
discussed in this chapter. These include renal insufficiency, 
jaundice, 
surgery 
sepsis and peri toni tis, 
and multiple trauma. 
respiratory 
The effects 
insufficiency, major 
of bile and of 
corticosteroids on the stomach are also briefly reviewed. 
The gastrointestinal effects of prostaglandins and cytoprotection 
are considered in chapter 4. Oral administration of the natural 
occurring prostaglandins appears to have little or no effects on 
gastric acid secretion. Administration of higher doses parenterally 
does decrease gastric acid secretion. Synthetic prostaglandins are 
capable of decreasing gastric acid secretion when given orally. This 
inhibition is mediated by direct effects of the prostaglandins on the 
parietal cells. 
Stimulation of the vagus nerve and administration of gastrin 
results in an increased concentration of prostaglandins in the lumen 
of the stomach. Prostaglandins appear to have a modulating effect on 
gastric acid secretion, similar to their modulating effects on renal 
blood flow or in inflammation. 
Cytoprotection was originally defined by Robert as the capacity of 
prostaglandins to protect the gastrointestinal epithelium against 
physical or chemical damage, which would otherwise lead to necrosis. 
This effect is not dependent on inhibition of gastric acid secretion. 
Subsequent experiments lead Robert to change this definition, as he 
found that the superficial epithelium was not protected, but only the 
underlying tissues. This suggests that the protective role of mucous 
and or other surface factors is limited, and that the cytoprotection 
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of prostaglandins is mediated by factors in the submucosa - either on 
a cellular level or via effects on the microcirculation. It remains an 
amazing observation that a small amount of prostaglandin, administered 
a few minutes before treatment, is capable of protecting the mucosa 
against such agressive agents as absolute alcohol or boiling water. 
Later on, it was shown that absolute alcohol did not affect the 
mucosal proliferative zone after pretreatment with prostaglandins. 
This zone produces within a few hours a new, normally functioning 
surface epithelial layer. 
Adaptive cytoprotection is an interesting phenomenon which occurs 
after application of mildly irritating substances to the mucosa, 
following which the mucosa becomes resistant against necrotizing 
agents. This effect is a rapid one, which has been shown to be 
mediated by prostaglandins. 
In animal experiments prostaglandins can prevent the development of 
various forms of stress ulcer. In humans the natural prostaglandin E2 
has been shown to prevent blood loss following aspirin or indomethacin 
·administration. Later endoscopic studies showed that the synthetic 
prostaglandin E2 prevented the development of gastric or duodenal 
lesions following aspirin ingestion. The healing of an existing peptic 
ulcer in the stomach or duodenum is facilitated by prostaglandins. 
Prolonged treatment with prostaglandins causes an increase in the 
thickness of the gastric mucosa, due to a decreased exfoliation of 
mucosal cells. All these findings suggested that prostaglandins might 
be useful in the prevention of stress ulcers in humans. 
In chapter 5 a clinical study is described which was designed to 
examine the possible beneficial clinical effects of prostaglandins in 
intensive care patients. In general, intensive care patients either 
receive no specific prophylaxis for stress ulcers, or are given either 
a histamine-2-antagonist (cimetidine or rani tidine), antacids or the 
combination of a histamine-2-antagonist and antacids. The frequency of 
stress bleeding during the use of cimetidine has been found to be 
approximately the same as during the use of placebo, as e.g. shown in 
the studies of Hastings et al, Priebe et al and Zinner et al. This 
drug is easy to administer, but is of little practical benefit in 
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stress ulcers. Administration of antacids without frequent examination 
of the pH of the stomach also appears to be of little benefit, while 
hourly titration of the gastric contents with antacids to a pH greater 
than 3.5 is very difficult to realize in practice. Antacids have many 
side-effects and they often cannot be administered because gastric 
suction is necessary. 
Prostaglandins are easy to administer and do not have side-effects 
when given in low dosage. To determine whetiler prostaglandins were 
indeed of practical benefit in the prevention of stress ulcers and 
stress bleed, a prospective, double-blind, placebo-controlled study 
was started. Prostaglandin E2 (PGE) which occurs naturally in the 
stomach, was chosen. The dosage was selected to be cytoprotective 
without reducing gastric acid secretion. For an acceptable evaluation 
a minimum of 3 observation days was considered necessary, while the 
study continued maximally for 7 days. Ninety patients with two or more 
risk factors (major operations, multiple trauma, respiratory 
insufficiency, renal insufficiency, jaundice, hypotension, peritonitis 
or sepsis) were randomized for treatment with either PGE2 0.5 mg or 
placebo given every 4 hours intragastrically. Blood loss in the 
51 gastric aspirates was measured quantitatively by means of the Cr 
labelled erythrocyte method. This method was chosen because we had 
doubts about the reliability of the qualitative tests for blood based 
on peroxidase reactions. In previous studies on the prophylaxis of 
stress bleeding in our hospital, we had found that patients fell into 
two groups: patients with less than 5 ml of blood loss per 24 hours 
and those with more than 15 ml of blood loss per 24 hours. We 
therefore chose a blood loss of 15 ml or more per 24 hours as evidence 
of mucosal damage and this was chosen as the lower limit for the 
diagnosis of hemorrhage. To compare our results with those of the 
literature, the gastric aspirates were also examined for the presence 
of blood by means of a peroxidase reaction, namely the orthotolidine 
test. The pH of the gastric aspirates were measured and samples were 
kept at -20°C for determination of the DNA concentration. Of the 
patients admitted to the study, 33 were not evaluable. The first 3 
days were often not completed due to transferral to another ward or 
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due to death, or because the gastric tube was removed. Oral feeding 
was not withheld from the patients because of the trial only. Of the 
57 patients who were evaluable, 29 received PGE2 and 28 placebo. 
Hemorrhage occurred in 9 of the PGE2 group (31%) and in 13 of the 
placebo group (46%). This difference is not statistically significant. 
In all instances of hemorrhage where gastroscopy and/or postmortem 
examination was performed, lesions were found, mainly in the stomach, 
but also in esophagus. 
the 51cr method in 
This provides evidence for the reliability of 
demonstrating upper gastrointestinal tract 
hemorrhage. However we should point out that we cannot be absolutely 
certain at all if blood in gastric aspirates is due to stress 
bleeding, as lesions were found in the esophagus and duodenum. 
The patients with stress bleeding had on average more risk factors 
than patients without bleeding, so that the number of risk factors 
does appear to be of prognostic importance. As could be expected, the 
number of risk factors also correlated with the mortality. Upper 
gastrointestinal bleeding was, however, rarely an important factor in 
mortality, a finding which diminishes the importance of stress 
bleeding prophyl~~is. 
The question is why PGE2 in this dosage and administered in this 
fashion does not prevent stress bleeding. The dosage was probably 
adequate, as similar dosages promote healing of duodenal ulcers and 
prevent blood loss following aspirin administration. Higher dosages 
would have led to diarrhea and abdominal cramps. The administration by 
means of dilution of an ampula of PGE2 in 20 ml of water and 
subsequent flushing of the nasogastric tube with 20 ml of water 
guaranteed that the drug was administered into the stomach. However 
the duration of exposition of the stomach and the portion of the 
stomach exposed to the PGE2 is not known. It is possible that mainly 
the antrum anri the posterior wall of the stomach were reached, and 
that the body and fundus of the stomach were not exposed sufficiently. 
Although there was no statistical significant difference in bleeding 
frequency, there was a difference. Theoretically, investigation of a 
larger number of patients could lead to a statistical significant 
difference in favour of PGE 2 . Continuation of the study however did 
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not seem indicated as we were attempting to obtain a drug which 
effects were not only statistically siginificant but also clinically 
significant. 
In chapter 6 the orthotolidine test, which is based on a peroxidase 
reaction, was found to be unsuitable for the determination or the 
detection of blood in gastric aspirates. In view of these findings the 
results of clinical studies on stress bleeding prophylaxis, which had 
been based on a peroxidase test, must be considered to be of doubtful 
significance. 
In chapter 7 a new method for determining blood in gastric 
aspirates is described, which is based on the determination of the 
concentration of haem in gastric juice. Treatment of haem by heating 
in the presence of a reducing acid solution results in the formation 
of fluorescing protoporphyrin. This method is, in contrast to the 
peroxidase test, reliable and quantitative and does not have the 
disadvantages of the 51cr-method. This method is probably a suitable 
tool for use in future studies of stress bleeding. 
In chapter S determination of DNA in gastric juice is described. No 
correlation could be found between DNA contents in gastric aspirates 
and PGE2 administration or physiological stress. 
In chapter 9 the treatment and prevention of stress bleeding, as 
described in the literature, is reviewed. Drug treatment is of little 
value once bleeding has started. Antacid administration is of value 
wi tb regard to preventing clot lysis, and vasopressin may have a 
beneficial effect if it is given selectively intra-arterially. The 
effects of transcatheter embolization need to be studied. Operative 
treatment is associated with a high mortality. 
As results of treating bleeding stress ulcers are poor, the 
rational approach would be to try to prevent ulcers. Some preventive 
effect bas been shown with varying therapies, without widespread 
clinical application following. It is an intriguing finding that the 
powerful gastric acid secretion stimulator, gastrin, can prevent the 
development of stress ulcers in rats. Histamine has also been shown to 
have this effect. In this chapter the clinical studies on stress 
bleeding prophylaxis using antacids or cimetidine are discussed. The 
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weak points in these studies are noted: the problems associated with 
demonstrating blood by means of peroxidase reactions on the one hand, 
and the insufficient increase of gastric pH by means of cimetidine on 
the other hand. Pirenzepine is theoretically a better agent for stress 
ulcer prophylaxis, as it has an effect on the mucosal 
microcirculation. Further clinical studies using this drug need to be 
performed. At present we do not know which treatment is indicated for 
the prevention of stress ulcers. Antacids and H2-antagonists have been 
shown to be effective in preventing Cushing's ulcer and Curling's 
ulcer, and patients admitted to an intensive care with a history of 
peptic ulcer would probably also benefit from these drugs. Prevention 
of stress ulcers and stress bleeds depends mainly on the active 
treatment of the risk factors and the administration of optimal 
parenteral nutrition and starting enteral feeding as soon as gastric 
suction is no longer required. 
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Sam en vatting 
In dit proefschrift is het stress ulcus syndroom beschreven. Dit 
wordt gezien bij patienten op afdelingen voor intensive care en in de 
veldhospi tal en bij oorlogs- en rampgebieden. Acute slijmvlieslaesies 
bij brandwonden (Curling's ulcers) en bij aandoeningen van het 
centrale zenuwstelsel (Cushing's ulcers) lijken een aparte 
pathofysiologie te hebben en een van het echte stress ulcus 
onderscheiden pathologie. Evenzo het ulcus pepticum en de maaglaesies 
bij gebruik van niet-steroide anti-inflammatoire middelen. 
In hoofdstuk 2 wordt de pathologie van het stress ulcus besproken. 
Ret stress ulcus in eigenlijke zin is meestal gelocaliseerd in het 
proximale dee! van de maag; zelden in het distale deel van de maag en 
in de dunne en dikke darm. Tot het begrip stress ulcus worden ook 
erosies gerekend, en het gaat histologisch om oppervlakkige laesies 
die zelden de muscularis propria bereiken. 
In hoofdstuk 3 wordt de pathofysiologie beschreven aan de hand van 
literatuurgegevens. Ret belang van de mucuslaag op het maagslijmvlies 
lijkt tot voor kort teveel te zijn benadrukt. De recente ontdekking 
van het vermogen van de maag om bicarbonaat te produceren, leidde tot 
het concept van de mucus-bicarbonaatbarri€re, met een aangetoonde 
pH-gradient over de mucuslaag. Daar prostaglandines zowel de 
bicarbonaatsecretie als de mucusproductie kunnen vergroten, lijken zij 
bij de maagslijmvliesbarri€re van grote betekenis. 
De rol van het maagzuur bij het ontstaan van stress ulcera wordt 
door velen sterk benadrukt. Het maagzuur lijkt echter in dit opzicht 
meer "permissive" dan oorzakelijk. 
Centraal bij het ontstaan van het stress ulcus is de systemische 
hypotensie, die tot mucosale ischaemie van de maag leidt. Ischaemie 
geeft intracellulair energietekort en vervolgens celnecrose. De 
studies van Menguy geven een goede verklaring voor het ontstaan van 
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stress ulcera op deze wijze, en maken ook bet spar en van het antrum 
van de maag begrijpelijk. 
Behalve hypotensie, c.q. shock, worden in dit hoofdstuk ook de 
andere risicofactoren besproken: nierinsufficientie, geelzucht, sepsis 
en peritonitis, respiratoire insufficientie, grate operaties en 
multipele traumata. In het kort komen de effecten op de maag van gal 
en van corticosteroiden aan de orde. 
In hoofdstuk 4 
prostaglandines en 
worden de gastro-intestinale 
de cytoprotectie besproken. 
effecten van 
De natuurlijk 
voorkomende prostaglandines hebben bij orale toediening geen of heel 
weinig remmende werking op de maagzuursecretie; bij parenterale 
toediening, in hoge dosering, wel. Synthetische prostaglandines kunnen 
bij toediening per os wel een goede zuursecretieremming geven. De 
zuursecretie wordt geinhibeerd door een direct effect op de parietale 
eel. 
Na vagusstimulatie en na toediening van gastrine worden 
prostaglandines in verhoogde concentratie in bet maaglumen gevonden. 
Prostaglandines lijken een modulerende werking te hebben op de 
maagzuursecretie, zoals ze ook modulerend werken bij de 
nierdoorbloeding en bij ontstekingsprocessen. 
Cytoprotectie werd oorspronkelijk door A. Robert gedefinieerd als 
het vermogen van prostaglandines het gastro-intestinale epi theel te 
beschermen tegen agentia, die anders necrose zouden geven. Dit effect 
is niet afhankelijk van maagzuursecretieremming. Latere onderzoekingen 
brachten Robert ertoe bovenstaande defini tie te wijzigen, daar hij 
vaststelde dat bet oppervlakte-epitheel niet wordt beschermd, maar wel 
bet weefsel daaronder. Dit wijst erop dat de beschermende rol van 
mucus en/of andere oppervlaktefactoren beperkt is, en dat 
prostaglandines cytop.rotectief werken via factoren in de submucosa: 
dus op cellulair niveau of rnicrocirculatoir. Het blijft een 
wonderlijke gebeurtenis dat een geringe hoeveelheid prostaglandine, 
enige minuten tevoren toegediend, het slijmvlies beschermt tegen zulke 
agressieve agentia als absolute alcohol en kokend water. Later werd 
aangetoond dat absolute alcohol de mucosale proliferatieve zone niet 
aantast na voorbehandeling met prostaglandines. Deze zone zorgt dan 
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binnen enige uren voor een nieuwe, normaal functionerende 
oppervlakte-epitheellaag. 
Adaptieve cytoprotectie is een interessant fenomeen, dat optreedt 
na toediening aan het slijmvlies van licht irriterende stoffen, 
waardoor het slijmvlies bestand is tegen necrotiserende agentia. Dit 
effect treedt ook snel in en het is aangetoond dat het door 
prostaglandines wordt gemedieerd. 
Dierproeven lieten zien dat prostaglandines diverse vormen van 
stress ulcera kunnen voorkomen. Bij de mens bleek het natuurlijke 
prostaglandine E 2 bloedverlies t. g. v. aspirine en indometacine te 
voorkomen. Later bleek ui t endoscopische studies dat synthetische 
prostaglandine E2 ook werkelijk laesies in maag en duodenum t. g. v. 
aspirine voorkomt. Ook de genezing van een bestaand ulcus pepticum in 
maag of duodenum wordt bevorderd door prostaglandines. 
Langere-termijnbehandeling met prostaglandines geeft toename van de 
dikte van de maagmucosa door verminderde exfoliatie van mucuscellen. 
Alle bovenstaande gegevens wijzen op een mogelijk preventief effect 
van prostaglandine tegen stress ulcus bij de mens. 
In hoofdstuk 5 wordt het eigen klinisch onderzoek beschreven dat 
erop gericht was bovenstaand gunstig klinisch effect bij intensive 
care patienten na te gaan. In de praktijk wordt tot nog toe aan 
intensive care patienten Of geen specifieke op stress ulcus prophylaxe 
gerichte medicatie gegeven Of men geeft een histamine-2-antagonist 
(cimetidine of ranitidine), Of alleen antacida, danwel de comb ina tie 
van histamine-2-antagonist en antacida. 
De frequentie van stress bleeding is bij gebruik van cimetidine 
ongeveer in dezelfde orde van grootte als bij placebo, zoals blijkt 
ui t de studies van Hastings et al, Priebe et al en Zinner et al. De 
toediening van dit middel is wel eenvoudig, maar de toepassing ervan 
a1s prophylacticum heeft geen goede wetenschappelijke basis. 
Antacidatoediening zonder frequente controle van de pH van het maagsap 
lijkt weinig zinvol, terwijl elk uur het maagsap titreren met antacida 
tot een pH ~ 3,5 in de praktijk vrijwel onuitvoerbaar is. Antacida 
hebben veel bijwerkingen en vaak is toepassing niet eens mogelijk 
omdat de maag moet worden gedecomprimeerd. 
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Prostaglandines zijn gemakkelijk toe te dienen en hebben bij lage 
dosering geen bijwerkingen. Om na te gaan of prostaglandine ook van 
praktisch nut is in de preventie van stress ulcus en stress bloeding, 
werd een prospectief, dubbel-blind, placebo-gecontroleerd onderzoek 
opgezet. Gekozen werd voor prostaglandine E2 (PGE2), dat natuurlijk in 
de maag voorkomt en daarom geen schadelijke bijwerkingen kan hebben. 
De dosering werd zodanig gekozen dat er geen zuursecretieremming 
optreedt, maar wel cytoprotectie. Voor een redelijke beoordeling werd 
een minimum van 3 observatiedagen nodig geacht, terwijl de studie 
maximaal 7 dagen liep. Negentig patienten met 2 of meer risicofactoren 
(grote operatie, multipele traumata, respiratoire insufficientie, 
nierinsufficientie, geelzucht, hypotensie, peritonitis, sepsis) werden 
gerandomiseerd voor behandeling met Of PGE2 0,5 mg Of placebo, elke 4 
uur intragastrisch 
kwanti tatief bepaald 
toegediend. Bloedverlies 
met de 51cr-methode. Voor 
in maagsap werd 
deze methode werd 
gekozen omdat wij twijfels hadden over de betrouwbaarheid van de op 
peroxidasereactie gebaseerde teststrookjes. In voorgaand onderzoek 
over stress bloeding prophylaxe in ons ziekenhuis werd gezien dat de 
meeste patienten <s ml bloedverlies/24 uur hadden, en er was een 
andere groep die ~15 ml bloedverlies/24 uur vertoonde. Daarom werd 
~15 ml bloedverlies/24 uur beschouwd als uiting van mucosale 
beschadiging en werd deze grens aangehouden voor de diagnose bloeding. 
Volledigheidshalve werd het maagsap ook onderzocht op bloed m.b.v. een 
op peroxidase-reactie gebaseerde teststrook, namelijk de 
ortho-toluidinetest. Ook werd de pH van het maagsap gemeten en er 
werden monsters bewaard voor latere bepaling van het DNA-gehal te. 
Uiteindelijk waren 33 patienten niet evalueerbaar. Vaak werden de 
eerste 3 dagen niet vol gemaakt door overplaatsing en door overlijden, 
of omdat de maagsonde werd verwijderd. Voeding per os werd niet aan de 
patient onthouden alleen terwille van de trial. Van de 57 evalueerbare 
patienten kregen er 29 PGE2 en 28 placebo. Bleeding trad op bij 9 van 
de PGE2 groep (31%) en bij 13 van de placebogroep (46%). Dit verschil 
is statistisch niet significant. 
In alle gevallen van bloeding waarbij gastroscopie en/of obductie 
werd verricht, werden ook laesies gevonden, meestal in de maag, maar 
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ook in slokdarm en maag. Dit geeft aan dat de 51cr-methode betrouwbaar 
is en geschikt voor het vaststellen van hoge tractus 
digestivusbloedingen. Tevens moet worden opgemerkt dat we niet zonder 
meer van stressbloeding kunnen spreken als er bloed in het maagsap 
wordt gevonden, daar er ook relatief vaak laesies in de slokdarm en 
het duodenum werden gevonden. 
De patienten met bleeding hadden gemiddeld meer risicofactoren dan 
de patienten zonder bloeding, zodat aan het aantal risicofactoren een 
prognostische betekenis kan worden toegekend ten aanzien van een 
eventuele bleeding. Zoals kon worden verwacht, was het aantal 
risicofactoren ook gecorreleerd met de mortaliteit. Een bleeding was 
echter zelden een belangrijke factor bij het overlijden. 
De vraag is waarom PGE2 in deze dosering en op deze wijze 
toegediend niet preventief werkt met betrekking tot stress bloeding. 
De dosering moet voldoende zijn geweest, daar bij dergelijke 
doseringen de genezing van ulcera duodeni werd bespoedigd en 
bloedverlies bij aspirinegebruik werd voorkomen. Hogere doseringen 
zouden overigens leiden tot diarrhoe en buikkrampen. De toediening: 
oplossen van een ampul PGE2 in 20 ml water en de maagslang naspoelen 
met 20 ml water, garandeert wel dat het middel in de maag komt. 
Echter, hoe lang het daar blij ft en welk deel van de maag wordt 
bereikt is niet zonder meer te zeggen. Overwogen moet worden dat het 
voornamelijk het antrum en de achterzijde van de maag wordt bereikt, 
en mogelijk corpus en fundus in onvoldoende mate. Hoewel er geen 
statistisch significant verschil in bloedingsfrequentie werd gezien, 
was er toch wel een verschil. Theoretisch zou onderzoek van een groter 
aantal patienten wel een statistisch verschil ten gunste van PGE2 op 
kunnen leveren. Voortzetting van de studie leek echter niet juist, 
daar we zoeken naar een effectief middel en omdat klinische relevantie 
belangrijker is dan statistische significantie. 
In hoofdstuk 6 wordt de ortho-toluidine test, die gebaseerd is op 
een peroxidasereactie, als ongeschikt voor de bepaling van bloed in 
maagsap beschreven. Op grond hiervan zijn de resultaten van de 
klinische onderzoekingen over stress bleeding prophylaxe, die 
gebaseerd waren op een peroxidase test, zeer twijfelachtig geworden. 
123 
In hoofdstuk 7 wordt een nieuwe bepaling van bloed in maagsap 
beschreven, die berust op bepaling van de haemconcentratie van het 
maagsap. Deze methode is, in tegenstelling tot de peroxidasetest, 
betrouwbaar en bovendien kwantitatief. en heeft niet de nadelen van de 
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cr-methode. In toekomstige trials over stress bleeding kan de 
haembepaling goede diensten bewijzen. 
Hoofdstuk 8 beschrijft de onderzoekingen betreffende DNA in 
maagsap. Uit de gevonden waarden kunnen geen conclusies worden 
getrokken met betrekking tot een effect van PGE2 of de ernst van de 
fysiologische stress. 
In hoofdstuk 9 wordt, aan de hand van literatuuronderzoek, de 
behandeling en vervolgens de preventie van stress bleeding beschreven. 
Bij een eenmaal opgetreden bloeding zijn medicamenten van beperkte 
waarde. Wel is toediening van van antacida zinvol met bet oog op de 
stolling en vasopressine is van nut indien het selectief 
intra-arterieel wordt toegediend. Het resultaat van 
transcatheterembolisatie dient te worden nagegaan, alvorens tot 
operatie wordt besloten, daar operatieve behandeling met een hoge 
mortaliteit gepaard gaat. 
Daar de behandelingsresul tat en van bloedende stress ulcera slecht 
zijn, is bet rationeel te proberen ulcera te voorkomen. Van 
verschillende middelen is enig preventief effect aangetoond, zonder 
dat klinische toepassing volgde. Het is een intrigerend gegeven dat 
een krachtige maagzuursecretie bevorderende stof, bet gastrine, stress 
ulcus bij de rat kan voorkomen. Ook histamine kan dit. In dit 
hoofdstuk worden de klinische studies over stress bleeding prophylaxe 
met behulp van antacida en cimetidine besproken. De zwakke punten 
daarin worden aangegeven: enerzijds de onbetrouwbare meting van bloed 
met op peroxidase reactie gebaseerde testmethoden en anderzijds de 
vaak onvoldoende verhoging van de pH van het maagsap bij gebruik van 
cimetidine. 
Wellicht is pirenzepine geschikt voor stress ulcus prophylaxe, daar 
het iets doet aan de mucosale microcirculatie. Verdere klinische 
onderzoekingen met dit middel lijken aangewezen. 
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Wij weten niet welk middel zinvol is bij de preventie van stress 
ulcus. Wei zijn voor de preventie van Cushing's ulcer en Curling's 
ulcer zowel antacida als H2-antagonisten effectief, en patienten op 
een intensive care met een anamnese van ulcus pepticum zijn met deze 
middelen wellicht ook gebaat. Preventie van stress ulcus en stress 
bloeding bestaat voornamelijk uit actieve behandeling van 
risicofactoren, en het geven van optimale parenterale voeding. 
Enterale voeding dient gegeven te worden zodra maagontlediging niet 
!anger nodig is. 
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Verantwoording 
Het in di t proefschrift beschreven onderzoek werd verricht op de 
afdeling Inwendige Geneeskunde II van het Academisch Ziekenhuis 
Dijkzigt te Rotterdam. Velen hebben daaraan meegewerkt, ook die van 
andere afdelingen. M. van Blankenstein initieerde de PGE
2 
trial. Hij 
en Prof. J.H.P. Wilson gaven mij steeds waardevolle adviezen. B. van 
den Berg van de afdeling Beademing had reeds dergelijk onderzoek over 
stress bleeding gedaan, zodat er een kader was waarin de nieuwe trial 
paste. De artsen en verpleegkundigen van de afdeling Beademing (3 Zuid 
I.C.; hoofd: Prof.dr. C. Hilvering) en van de chirurgische Intensive 
Care (10 Zuid I.C.; hoofd: Dr. H.A. Bruining) waren mij steeds 
behulpzaam. De verpleging diende nauwgezet de medicatie toe en heeft 
met veel geduld de talloze zakjes maagsap verzameld en bewaard. 
Op de afdeling Nucleaire Geneeskunde (hoofd: Drs. W.H. Bakker) werd 
ik ingevoerd in de techniek van het labelen van erythrocyten. Agnes de 
Lange-Macdaniel bood mij vaak de helpende hand. 
P.J.M. Schmitz gaf advies voor statistische beoordeling. 
Het Centraal Klinisch Chemisch Laboratorium (hoofd: Dr. B.G. 
Blijenberg) was bereid de zoutzuurbepaling van de vele maagsapmonsters 
uit te voeren. De analisten, onder wie G.C. Verheij, wisten in korte 
tijd de uitslagen te leveren. 
Op het Laboratorium Interne II was ik te gast voor specieel 
onderzoek van maagsap. De biochemici Dr. W.H.O. van den Berg en Dr. 
F.W.M. de Rooij hebben mij op prettige wijze begeleid. Datzelfde geldt 
voor de analisten, die ook een deel van het werk deden; van hen wil ik 
Rita Koole-Lesuis en Trinet Rietveld met name noemen. 
Nienke Essed, patholoog-anatome, verstrekte mij fotomateriaal. 
De patienten en hun familie, die toestemming gaven voor het 
klinisch onderzoek, ben ik erkentelijk. 
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De firma Upjohn (Kalamazoo) leverde de ampullen met prostaglandine 
en placebo voor dit onderzoek. 
Ellis van der Waarde-Masthoff wil ik bijzonder danken voor het 
accuraat uittypen op de tekstverwerker van mijn manuscripten. 
Mijn promotor, Prof. J .H.P. Wilson, heeft mij op zeer prettige 
wijze begeleid en talrijke praktische tips gegeven. 
Tenslotte vooral dank aan mijn vrouw Marjolein, die ondanks de zorg 
voor jonge kinderen, een sfeer verschafte die het mogelijk maakte dit 
proefschrift tot stand te brengen. 
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Curriculum vitae. 
De schrijver van dit proefschrift werd op 2 oktober 1948 te 
Barneveld geboren. Na bet behalen van het diploma HBS-B aan het 
Christelijk Streeklyceum te Ede in 1968, studeerde hij farmacie aan de 
Rijksuniversiteit te Utrecht, waar hij in 1971 slaagde voor het 
kandidaatsexamen. Daarna werd de studie geneeskunde aangevangen, ook 
te Utrecht. Het doctoraal diploma werd in 1976 ui tgereikt met de 
toevoeging "met genoegen". Op 23 maart 1977 werd het artsexamen 
afgelegd. Op 1 mei 1977 begon hij aan de opleiding tot internist in 
het Havenziekenhuis te Rotterdam (opleider: Dr. P.C. Stuiver), die in 
1979 werd voortgezet in bet Gemeenteziekenhuis te Dordrecht (opleider: 
Dr. B.A. de Planque). In het kader van het vrije jaar van de 
opleiding, ging hij in 1981 naar het Academisch Ziekenhuis Dijkzigt te 
Rotterdam, afdeling Inwendige Geneeskunde II (hoofd: Prof.dr. M. 
Frenkel), teneinde het in di t proefschrift beschreven onderzoek te 
verrichten en zich te bekwamen in de gastro-enterologie. Op 1 mei !982 
werd hij in het specialistenregister ingeschreven. Het klinisch 
onderzoek werd in september 1983 afgesloten. Daarna volgde een 
waarneming in de Stichting Oosterschelde Ziekenhuizen te Goes. Sinds 1 
juli 1984 is hij werkzaam als internist, in het bijzonder voor de 
gastro-enterologie, in het St. Clara Ziekenhuis te Rotterdam. 
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